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-CHAPTER I 
INTRODUCTION AND REVIEW OF LITERATURE 
Biophysical Anesthetic Mechanism 
The study of the mechanism of anesthetic action 
has been approached by a surprisingly diverse group of 
disciplines. These studies have arisen from almost every 
type of laboratory in the biological and chemical sciences. 
The resulting milieu is clouded and filled with many 
diverse theories. With this in mind, I have taken the 
liberty to group these theories into two subgroups, the 
protein theories and the lipid theories, in an attempt to 
gain semblance. First, a few basic concepts should be 
considered to help gain insight into these theories which 
suggest a unitary molecular site of anesthetic action. 
General anesthesia is produced by a wide variety 
of compounds with no common chemical structur~ or chemical 
activity. Some examples of the diverse chemical natures 
of agents that produce general anesthesia would include 
aliphatic, aromatic, halogenated hydrocarbons, alcohols, 
aldehydes, ketones, esters, and ethers (Kaufman, 1977). 
Even the nitrogen in the air we breathe has anesthetic 
1 
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properties (Paton, 1967; Winter, et al ., 1975). Important-
ly, it has been suggested that a specific receptor does 
not play a significant role in anesthetic mechanisms. 
This has been proposed largely for two reasons. First, 
the molecular size differential between a small molecule 
(e.g., N20) and a large molecule (e.g., a steroidal 
anesthetic) makes the feasibility of such a relationship 
unlikely. Second, stereoisomerism is an important criterion 
for receptor delineation: stereoisomers of most anesthet-
ics are equipotent (Kendig, et al ., 1973). 
For many years it has been known that hydrostatic 
-pressure can modify an organism•s response to drugs 
(Cattel, 1936). In fact, anesthesia itself is generally 
reversed with increased atmospheric pressure. Johnson and 
Flagler (1950) first made the observation that tadpoles 
narcotized with a 2 - 5% ~thanol would resume swimming in 
an apparently normal manner following application of 
pressure. Similar hyperbaric reversal of anesthesia has 
been demonstrated for ether, halothane, barbiturates, and 
nitrous oxide. Even though much work remains to be done 
in this field, pressure reversibility of anesthesia is an 
important aspect in the consideration of anesthetic 
biophysical models. 
---
3 
Lipid Theory 
The first and certainly the most successful 
biophysical theory of anesthetic mechanisms arose from the 
observations of Meyer (1899) and Overton (1901). This 
theory, the lipid solubility theory of anesthetics, was 
best stated in Meyer's 1937 paper: "Narcosis commences 
when any chemically indifferent substance has attained a 
certain molar concentration in the lipids of the cell. 
This concentration depends on the nature of the animal or 
cell, but is independent of the narcotic." 
In 1954, Mullins reformulated the lipid theory of 
anesthesia resulting in the critical volume theory which, 
even today, acts as a basis for lipid theories of anes-
thesia. The critical volume hypothesis is based on a 
simple model of solvents. It accounts accurately for both 
the relative potencies of gaseous anesthetics and for 
pressure reversal of anesthesia. Simply stated the theory 
proposes that anesthesia commences when a certain critical 
volume fraction of an inert substance is attained in 
membranes. The critical volume of an anesthetic entering 
the membrane can be thought of as that volume which fills 
up the free volume of the membrane. The resulting compres-
sion caused by a volume increase in the membrane lipid 
bilayer influences the membrane proteins essential to 
4 
neural function. Mull ins believed the resultant protein 
modification would effect sodium or potassium channels, 
neurotransmitter receptor conformation, or enzyme systems 
that affect neurotransmitters. Highly specific supportive 
evidence to affirm this theory comes from the theory's 
capability to predict both the excitation of the nervous 
system at high pressure (high pressure neurological 
syndrome; Miller, 1974) and the pressure reversibility of 
anesthesia. Three subsequent interpretations of the 
critical volume theory have recently surfaced: (a) the 
fluidized lipid hypothesis, (b) the phase transition 
hypothesis and (c) the lateral phase separation hypothesis. 
(a) Fluidized Lipid Hypothesis: 
The original critical volume hypothesis pro-
posed by Mullins suggested that the anesthetic filled 
up the 11 free volume 11 in the membrane in such a way as 
not to allow for protein accommodation necessary for 
nerve function. Work by Hubbell et al. (1970), and 
Seeman (1975) has not supported this "free volume .. 
concept. Instead, the critical volume of anesthetic 
entering the membrane was thought to expand the mem-
brane. The resulting disorder caused by the volume 
increase in the membrane lipid bilayer would result 
-in decreased membrane viscosity. Although this theory 
modification does not address itself directly to the 
problem of how a fluidized membrane might interfere with 
nerve performance, and therefore anesthesia, it does 
correct the critical volume theory in the light of the 
5 
new data. Gage and Hamill (1976) attempted to link the fluidized 
membrane with its physiological performance. He suggested 
a decrease in membrane viscosity as affecting the function 
of the membrane ionophores and thus membrane polarization. 
(b) Phase Transition Hypothesis: 
The phase transition hypothesis of Lee (1976) has 
an advantage over the fluidized lipid hypothesis in that 
it provides a direct mechanism by which the anesthetic 
agents effect nerve function. He postulates an annulus 
lipid structure in the gel state gating the sodium channel. 
The excitable protein is 11 COntrolled" by this lipid annulus 
and thus this lipid hypothesis has a direct link between 
lipid and protein mechanisms. Specifically, this theory 
states that "an anesthetic agent •melts• (phase transition) 
the lipid annulus stabilizing the channel in its closed 
state. 11 
(c) Lateral Phase Separation: 
The last of the three modifications dealing with 
p 
the critical volume theory was originally proposed by 
Shimshick and McConnel (1973), however Trudell (1977) 
later incorporated Shimshick's theory into a unitary 
theory of anesthesia based on lateral phase separation. 
6 
As defined by Shimshick, "lateral phase separation occurs 
in phospholipid bilayer membranes when highly ordered gel 
phase phospholipids and disordered fluid-phase phospho-
lipids coexist." The borders between solid and fluid-phase 
in a phospholipid bilayer are called lateral phase separa-
tions. Accordingly, the phospholipid bilayer is able to 
accommodate volume change by transforming high volume 
disordered chains to lower-volume ordered chains (Shimshick 
and McConnell, 1973). This is termed lateral compressi-
bility. As stated previously, proteins have been shown to 
change conformation during normal function (Low and 
Somera, 1975) and during anesthesia (Seeman, 1972). This 
evidence suggests that lateral compressibility is necessary 
for some cellular processes. Steer and Levitzki (1973) and 
Bretscher and Raff (1975) have in fact described phase 
transition in lipid surrounding enzyme systems and membrane 
proteins in mammals. The lateral phase theory goes on to 
suggest that application of an anesthetic agent to the 
membrane bilayer results in a disordered configuration of 
fatty-acid chains near the protein with no lateral 
7 
compressibility. Once disordered by the anesthetic agent 
the protein would require a large amount of energy in order 
to expand or change configuration. In effect, the lipid 
is not able to assume its lower volume solid phase necessary 
for protein rearrangement. When a sufficient number of 
nerve membrane protein molecules are functionally blocked 
the cell or organism is then anesthetized. 
Various models dealing with protein conformation 
changes necessary for nerve function are discussed in the 
section on protein theories of anesthesia. It is important 
to note at this time that each of the protein theories to 
be discussed in that section could be adequately explained 
in terms of lateral compressibility. One theory unrelated 
to a protein mechanism was proposed by Taupin and McConnel 
(1975) and later by Van der Bosch and McConnel (1975) 
suggesting that lateral phase separation blocks exocitosis 
without protein involvement. 
• 
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Protein Related Biophysical Anesthetic Mechanism Theories 
The rationale of an anesthetic-protein interaction 
in the past has been questioned. This was due to the well 
known fact that anesthetics are highly lipid soluble 
(hydrophilic) while protein molecules are generally polar 
(hydrophobic) making protein an unlikely locus for anes-
thetic action. With current knowledge of protein structure 
many amino acid residues have been considered to be 
hydrophobic when in peptide side chains. These amino acids 
are glycine, alanine. valine, leucine, isoleucine, proline, 
phenylalanine, and methionine. If anesthetic agents do 
work directly upon protein it would be these lipid soluble 
amino acids of the side chains that interact with the 
anesthetic agents. 
Further support for a direct anesthetic-protein 
interaction came from Balasubramanian and Wetlaufer (1966). 
They confirmed that gaseous anesthetics interact with 
protein and changed the conformation of the protein side 
chains without affecting the basic a-helical configuration 
of the peptide chains. Schoenborn (1968) and Schoenborn 
et al. (1965) have further delineated these sites. For 
historical continuity, each theory will be discussed. 
a) Surface Tension Theory: 
The first of the protein theories began possibly 
• 
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with Traube (1904) and Lillie (1909). They observed that 
anesthetic potency could be related to the ability to lower 
surface tension. To elucidate the mechanism Clements and 
Wilson (1962) reformulated earlier theories of Lillie 
(1909) and Warburg (1921) describing the interaction 
of general anesthetics with surface films of protein. An 
alteration of the surface protein was proposed to cause a 
change in neural transmission and thus cause anesthesia. 
The surface tension theory is, historically, the origin 
of the current day protein conformational change theory 
to be discussed later. 
b) Colloid Theories: 
A second protein theory had its origin in the late 
eighteenth century. Proposed by Claude Bernard in 1875, 
and formalized by Bancroft and Richter in 1931, the 
colloid theory suggested reversible aggregation of all 
colloids causing anesthesia. Reversible cessation of 
protoplasmic streaming has been demonstrated in slime mold 
following the addition of chloroform, cyclopropane and 
ethylchloride (Seifritz, 1950). Heilbrunn (1952) observed 
that viscosity of the cytoplasm of slime molds and algae 
was decreased by low anesthetic concentrations and 
increased by high concentrations. Bruce and Christiansen 
p 
(1966) showed that diethyl ether and halothane inhibited 
protoplasmic streaming in the amoeba. 
The colloid theory culminated in the current 
10 
day microtubule theory. Proposed in 1968 by Allison and 
Nunn, microtubule inhibition was suggested as the underly-
ing mechanism by which the anesthetic agent produced 
viscosity changes and anesthesia. Subsequently, Allison 
et al. (1970) demonstrated that five inhalation anesthetics 
produce reversible dispersion of microtubules in heliozoa 
at concentrations of 2 to 4 MAC (minimum alveolar concen-
tration) and nitrous oxide at concentrations below 1 MAC. 
The relevance of these findings to the understand-
ing of anesthesia is questionable. Other investigators 
have failed to show an effect of pentobarbital and 
halothane on microtubules in mouse optic nerve (Sauberman 
and Gallagher, 1973). It was also demonstrated that 
squid axons continued to conduct action potentials 
following removal of 95% of the axoplasm which suggests 
that microtubules are not necessary for axonal conduction. 
Colchicine, podophyllotoxin, vinblastine, and griseofulvin 
each have the ability to disrupt the microtubule system. 
Katz (1972) found that colchicine and podophyllotoxin 
decrease transmitter release from frog neuromuscular 
junction, however, as these drugs were shown to act on 
nerve terminal membranes, he concluded that the effects on 
11 
transmitter release were independent of microtubular 
effects. Further, colchicine and vinblastine inhibited 
acetycholine-induced catecholamine release from the 
perfused bovine adrenal gland and blocked transmission 
through the superior cervical ganglia of the cat (Trifaro 
et al ., 1972), actions which were attributed to the 
anti-cholinergic effects of these drugs and not to 
microtubular actions. Further problems shrouding this 
theory include its inability to account for pressure 
reversibility of anesthesia (Salmon, 1975) and the ability 
of anesthetics to release calcium with only incidental 
effects on microtubules. Supporters will, however, cite 
variability of microtubules within individual cells 
(Behnke and Forer, 1967) and between cell types and 
species as the cause of the discrepancies (Olmsted et al ., 
1971). As a result of the conflicting data and a general 
lack of investigative support, the microtubule theory of 
anesthetic action has not been well accepted. 
c) Protein Conformational Change Theory: 
The most favorable protein related anesthetic 
mechanism theory revolves around protein conformational 
changes as a result of anesthesia. This theory stems from 
both the surface tension theory (previously discussed) and 
from a bacterial enzyme model. 
..... 
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Photobacterium phosphoreum possess a light produc-
ing system which is sensitive to anesthesia. This light 
production results from the interaction of the enzyme 
luciferase with reduced flavin mononucleotide and oxygen. 
The light emission is proportional to the reaction velocity 
(Johnson and Eyring, 1948). It has been shown that a wide 
variety of anesthetic agents, including halothane, 
chloroform, cyclopropane, and ether at equipotent clinical 
anesthetic doses produces an inhibition of luminescence of 
this type which is reversible by application of hyperbaric 
pressure (Johnson et al ., 1942; White and Dundas, 1970; 
Halsey and Smith, 1970). The anesthetic produced inhibi-
tion of luminescence is believed to be due to a conforma-
tional change of the luciferase enzyme. 
Seeman (1972) and Low and Somero (1975), who have 
demonstrated membrane expansion associated with anesthesia, 
found that the increase in membrane volume was about 10 
times the occupying volume of the anesthetic in the mem-
brane protein suggesting conformational changes in the 
membrane protein. Eyring (1973) suggested this conforma-
tional change resulted from membrane unfolding such that 
the membrane occupied a larger volume. In this connection, 
Eyring (1973) has described the effect of anesthetics on 
protein conformational change in terms of a thermodynamic 
change. Hill (1974) proposed a thermodynamic description 
p 
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of general anesthesia in terms of the "Gibbs" free energy 
of the anesthetic site. The advantage of Hill's theory 
is that the outcome of the interaction can be predicted 
without knowledge of the mechanistic details of that 
process. 
Thermodynamic analysis of firefly luminescence 
has been applied by Ueda and Kamaya (1973) to the anes-
thetic action of methoxyflurane, chloroform, halothane, 
enflurane and fluroxene suggesting their site of action 
at a hydrophobic site on luciferase inducing a structural 
membrane 11 Unfolding ... 
There are many ways by which protein conformational 
change may affect neural function. Protein conformational 
change or "unfolding" may (a) prevent the association of 
protein into ion channels, (b) depress the transmitter 
release by preventing vesicular and presynaptic membrane 
fusion, (c) inhibit rate limiting enzymes, or (d) affect 
the postsynaptic membrane receptor. Any or all of these 
effects may be involved. 
Although not as well supported as the lipoid 
anesthetic model, the protein-based anesthetic interaction 
model is certainly viable. It is also clear that no 
single theory will explain the effects of all anesthetic 
agents. A hydrophobic protein site of action can explain 
many of the physiochemical relationships cited. 
• 
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An important common denominator between all 
theories developed that must be stressed is that, at best, 
all of these theories are descriptive in nature. They 
describe the effect of anesthetics rather than a mechanism 
by which these effects are produced. 
p 
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Other Proposed Biophysical Mechanisms of Anesthetic Action 
Two seemingly important models for anesthetic 
action were proposed independently by Miller (1961) and 
Pauling (1961) and were popularized in the past decade. 
These theories fit neither the protein nor the lipid 
theories of anesthesia. Pauling and Miller each suggested 
that the site of action of anesthetics lies in the aqueous 
water phase of the nerve cell. Both investigators 
established a relationship between anesthetic potency and 
highly ordered water molecules orientated around aqueous 
solutions of gases (i.e., hydrated crystals). Pauling 
(1961) suggested the formation of mixed hydrates of 
solutes in brain fluid and charged side-chains of protein 
which are capable of forming stable hydrate substructures. 
These hydrated microcrystals, or 11 Clathrates, 11 once 
formed, were to result in increased neural impedance, 
ionophore blockage, or altered enzymatic activity. Both 
theories have died from lack of evidence that clathrates 
form at normal body temperatures. 
p 
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Macromolecular Site of Anesthetic Action 
The theories of anesthesia developed thus far have 
proposed or alluded to a specific biomolecular locus of 
anesthetic action. However, it becomes apparent from a 
review of the literature that-sufficient evidence exists. 
to imply that anesthetics have their primary neuronal ac-
tion in the synaptic region at the macromolecular level 
(Alper and Flacke, 1969; Brooks and Eccles, 1947; de Jong 
et al ., 1968a; de Jong and Nace, 1967; DeRobertis, 1971; 
Halsey and Smith, 1970; Ho and Keats, 1969; Karis et al ., 
1966, 1967; Larrabee and Pasternak, 1952; Paton and 
Speden, 1965; Richards, 1972, 1973). Investigations into 
anesthetic effects on synaptic elements have raised 
several important questions: Is the anesthetic action on 
the synapse due to a direct lipid and/or protein inter-
action as suggested in the previously discussed theories? 
Do anesthetics affect pre- or postsynaptic elements or 
both? 
It is widely believed that for a general anes-
thetic to have effect on a synapse it must directly or 
indirectly cause the depression of nerve impulse conduc-
tion, depress presynap!ic transmitter release, result in 
postsynaptic membrane conductance changes, or induce a 
combination of these effects ultimately leading to a 
depression of certain synapses in the central nervous 
p 
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system. Balasubramanian and Wetlaufer (1966), Ho and 
Keats (1969), Musick and Hubbard (1972) and others 
consider these basic nerve functions to be performed by 
membrane lipoproteins. When considering the argument 
between lipid or protein anesthetic interaction, Woodbury 
et al. (1976) wittily suggested 11 the parallelism between 
the effects of anesthetics on lipids and proteins suggest 
that research in these two fields are feeling different 
parts of the same elephant. 11 As to which mechanism is 
actually responsible for the anesthetic induced reduction 
in synaptic transmission, it is too early to postulate. 
There are many reputed central neurotransmitter 
systems (i.e., cholinergic, adrenergic, gabaminergic, 
and serotonergic). Whether anesthetic agents affect all 
transmitter system synapses uniformly or only select 
transmitter systems in a discrete fashion has not been 
determined. 
This dissertation examines the effects of certain 
anesthetic agents on the central adrenergic nervous 
system. A review of the known central adrenergic pathways 
follows. 
18 
Adrenergic Neuropathways 
Dopamine (DA) and norepinephrine (NE), each a 
catecholamine, are considered to be putative neurotrans-
mitters in the mammalian central nervous system. 
Norepinephrine was first detected in the mammalian brain 
by von Euler (1946). Vogt (1954) later found that the 
concentration of NE in brain was not evenly distributed 
and did not parallel brain vasculature. Von Euler further 
demonstrated a close correlation between the content of 
NE present and the proportion of nonmyelinated to mye-
linated nerve fibers. Further, hypotha 1 ami c NE 
concentration was found to be unaltered by cervical 
sympathectomy. These early findings led investigators to 
propose a role for NE as a central neurotransmitter. 
Dopamine, initially believed to be present in 
mammalian brain solely as a precursor of NE (Carlsson, 
1966), was found to be present in whole brain in concen-
trations higher than NE (Montagu, 1957; Weil-Malherbe 
and Bone, 1957). Later DA studies demonstrated a 
distribution markedly different from that of NE (Cooper 
et al., 1974). 
Many studies have been subsequently performed to 
establish the role of both NE and DA as central adrenergic 
neurotransmitters. Specific areas of catecholamine 
research establishing their putative roles in the central 
p 
nervous system have been extensively reviewed in the 
literature. (For reviews of specific areas cf.: 
Biochemistry, Molinoff and Axelrod (1971 ); Function, 
Hornykiewicz (1966), and Marley and Stephenson (1972); 
Metabolism, Axelrod (1966 and 1971 ), Glowinski and 
Baldessarini (1966), and Kopin (1972); Pharmacology, 
Salmoiraghi et al. (1965), and Sulser and Sanders-Bush 
(1971 ); Receptors, Curtis and Crawford (1969), and 
19 
Triggle (1972); Release, Glowinski (1970), andSmith et al. 
(1977); Synthesis, Kopin (1968), Axelrod (1971), and 
Costa and Meed (1974); Transport and Storage, Glowinski 
(1970), and Shore (1972); Uptake, Iversen (1970 and 
1971)). 
Instrumental in outlining the central anatomical 
pathways of the catecholaminergic neurons have been 
fluorescence methodologies. First developed by a Swedish 
research group headed by Eranko (1955) and later improved 
by Falck and Hillarp (Falck et al., 1962; Falck, 1962) 
catecholamine neurons were shown to fluoresce when exposed 
to vaporized formalin. Lindvall and Bjorklund (1974) and 
Lindvall et al. (1974) have recently introduced the use of 
glyoxylic acid instead of formaldehyde to produce monamine 
fluorescence of greater intensity. Since the amount of 
fluorescence produced is proportional to the amount of 
catecholamine present, several techniques are usually 
employed to alter endogenous catecholamine levels and 
·therefore change fluorescence visibility. This includes 
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drugs such as reserpine and monoamine oxidase inhibitors, 
lesioning to increase proximal axonal amine content 
(Anden et al ., 1974; Ungerstedt, 1971 ), and cytotoxic 
compounds for system delineation (Snyder et al ., 1970a; 
Ungerstedt, 1968; Baumgarten et al ., 1971 ). 
Recent developments have led to the introduction 
of a highly sensitive and selective immunocytochemical 
peroxidase-antiperoxidase system to identify and localize 
enzymes necessary for catecholamine production. A com-
parison of data from existing techniques leads to the 
delineation of distinct dopaminergic and noradrenergic 
pathways (cf. below). 
Dopaminergic Pathways: 
The majority of dopaminergic cell bodies lie in 
mesencephalon and give rise to an estimated 500,000 
terminals (Cooper et al., 1974). Three primary dopaminer-
gic pathways have been proposed. Each of the three 
pathways has been established with a large variety of 
techniques, including fluorescence histochemistry, bio-
chemistry, stains of terminal degeneration, and electron 
microscopy (for a more extensive review of the literature 
on techniques specific for DA cf. Moore and Dominic, 
p: 
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1971; Carpenter and Peter, 1972). 
a) The Nigrostriatal System: 
The first dopaminergic pathway to be discussed is 
the nigrostriatal system (i.e., cell groups A8 and A9, of 
Dahlstrom and Fuxe, 1964). The substantia nigra is the 
largest nuclear mass in the mesencephalon (Carpenter and Peter, 
1972). The cell bodies lie primarily in the zona compacta 
of the substantia nigra and project through the medial 
forebrain bundle to the striate and amygdaloid nuclei. 
Specific fibers in the caudal two-thirds of the nigra 
project to portions of the putamen, while rostral parts 
of the nigra project to the caudate nucleus. 
It has been suggested that this nigro-neostriatal 
dopaminergic system is related to the extrapyramidal motor 
system. As to whether this is its sole action is yet to 
be determined. Neurophysiologic data in support of this 
pathway has shown that iontophoretically applied DA 
to neurons of the cat caudate nucleus causes depression of 
spontaneous neuronal firing (Connor, 1972). An identical 
response was elicited by electrical stimulation of the 
substantia nigra. Both nigral stimulation and iontophore-
tic DA application were shown to be blocked by a-methyl-
dopamine. It has been suggested that DA has an inhibitory 
action at the caudate nucleus when released from cells 
originating in the substantia nigra. In contrast, York 
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foJnd iontophoretically applied DA caused a facilitation 
of neuronal firing in the cat putamen. Electrical stimu-
lation of the substantia nigra elicited a similar 
facilitation thus both facilitatory and inhibitory actions 
of DA have been demonstrated (York, 1970). 
b) The Mesolimbic System: 
The second of the thrie DA pathways to be discussed 
is the mesolimbic dopaminergic pathway. The cell bodies 
for these nerves arise in the medial mesencephalon just 
dorsal to the interpeduncular nucleus (cell group AlO, 
Dahlstrom and Fuxe, 1964); these fibers ascend medially to 
the crus cerebri into the medial forebrain bundle 
innervating the tuberculum offactorium and the nucleus 
accumbens. These nerve bundles run lateral to noradrener-
gic nerve tracts innervating the neostriatum. The 
function of the mesolimbic dopamine system is at present 
unknown. 
c) The Tuberoinfundibular System: 
The cell bodies of the third known dopaminergic 
system lie primarily in the arcuate nucleus of the 
hypothalamus (Dahlstrom and Fuxe, 1964, cell groups #All-
12). They innervate the external layer of the medial 
eminence. The dopaminergic neurons in this last system 
behave differently from those found in the nigrostriatal 
p 
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or mesolimbic system. The tuberoinfundibular system is 
insensitive to the normal destructive action of 6-
hydroxydopamine and when activated for any length of time 
becomes markedly depleted of transmitter stores. It has 
been suggested that the neurons in the system behave in a 
manner similar to that of neurosecretory neurons. 
Noradrenergic Pathways: 
Noradrenergic cells give rise to large collateral 
networks of fibers innervating many brain areas. As an 
example of this system's diffuse nature it has been shown 
that in the case of the locus coeruleus one noradrenergic 
cell body sends tracts to both the cerebral cortex and 
the cerebellum. The central noradrenergic system has both 
ascending and descending tracts, most of which originate 
in the pons and medulla oblongata. Noradrenergic fibers 
have been shown to innervate the thalamus, the preoptic 
area, the amygdaloid nucleus, the hippocampus, cingulate 
gyrus, the pyriform cortex, the striatal terminalis, the 
septal areas, the neocortex, and several hypothalamic 
nuclei. The ascending noradrenergic system has its cells 
of origin in the medulla and pons, Dahlstrom and Fuxe 
(1964), areas A-1, A-2, A-5, A-6, and A7. 
Due to the diffuse projections of the noradrenergic 
systems it is easier to construct a general picture of this 
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system by considering the four major noradrenergic conduc-
tion pathways: (a) the central tegmental tract, (b) dorsal 
tegmental bundle, (c) the periventricular fiber system, 
and (d) the medial forebrain bundle. A brief description 
will follow for each. A more complete description is 
included in the works of Dahlstrom and Fuxe (1964), 
Ungerstedt (1971 ), and Lindvall and Bjorklund (1974). 
(a) The central tegmental tract (CTT) 
The central tegmental tract is usually considered 
to be a highly heterogeneous system of longitudinally 
running fibers in the reticular fo~mation. The ascending 
system is comprised of cells originating in three loca-
tions: (1) spinal cord, (2) the medullary reticular 
formation (groups Al and A2), and (3) the pons (from cell 
group AS situated lateral to the superior olivary nucleus, 
A7, the subcoeruleus, and A6, the locus coeruleus). 
Lindvall and Bjorklund (1974) also reported vertical 
T-shaped noradrenergic fibers in this pathway interconnect-
ing the CTT with the periventricular grey. Chu and Bloom 
(1974) and Lindvall and Bjorklund (1974) have suggested 
that these vertically arranged fiber systems represent 
collateral branches from the CTT to give rise to an 
extensive terminal system distributed in the locus 
coeruleus, dorsal raphe nucleus, and the periventricular 
grey system. 
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(b) Dorsal tegmental bundle (DTB) 
The dorsal tegmental bundle is an ascending 
homogeneous group of noradrenergic fibers arising from 
the locus coeruleus (A6). Soon after the DTB emerges 
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from the locus coeruleus, the crossing fibers deviate 
medially from the DTB. Along its course the tract ascends 
lateral to the medial longitudinal fasciculus. While still 
in the mesencephalon, the DTB gives off fibers just 
rostral to the decussation of the superior cerebellar 
peduncles (i.e., at the level of the inferior colliculus) 
to the tegmental radiation. At the meso-diencephalon 
junction the DTB runs ventrolateral to the periventricular 
grey of the third ventricle. Dopaminergic All cells of 
the caudal thalamus have been observed to project axons 
into the DTB. The DTB then courses through the hypothala-
mus giving rise to several branches that innervate the 
thalamus (Lindvall et al ., 1974) ~ Past the hypothalamus 
the DTB merges with the medial forebrain bundle. Shortly 
before the DTB joins the medial forebrain bundle, it 
gives rise to fibers that run with the nigrostriatal DA 
system. 
(c) The periventricular system: 
The periventricular system is composed of two 
subsystems, the dorsal periventricular system (DPS) and 
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the ventral periventricular system (VPS). The DPS extends 
from the periventricular and periaqueductal grey of the 
medulla oblongata through the pons and mesencephalon to 
the rostral portions of the diencephalon and septum. Some 
of the cells of origin are located in the locus coeruleus 
and are quite different from other catecholamine systems. 
Many of the cell bodies are distributed diffusely from 
the pons through the mesencephalon to the posterior thala-
mus. In addition, fibers from the cell groups A2, A4, and 
area postrema may be present (Dahlstrom and Fuxe, 1964). This 
system has been shown to project to the medial thalamic, 
epithalamic, pretectal, and hypothalamic regions. Projec-
tions to the tegmental radiations, medial forebrain bundle, 
and dorsal raphe nucleus have also been demonstrated. 
Lindvall and Bjorklund (1974) have suggested that this 
system is composed of relatively short fiber systems that 
originate at different levels of the OPS and run for some 
distance along the bundle to terminate either locally in 
the central grey or at higher levels. This system, they 
suggest, can be regarded as an adrenergic component of 
the dorsal longitudinal fasciculus. (The dorsal longitudi-
nal fasciculus carries fibers from the dorsal tegmental 
nucleus. Their function seems to be a rhinencephalic 
relay to brain stem nuclei.) 
The second periventricular system, the VPS, is 
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less well defined. It is formed at the meso-diencephalic 
junction from converging tegmental radiation fibers as is 
the medial forebrain bundle. It is believed to run from 
the interpeduncular nucleus rostrally to the mamillothala-
mic tract. At this location, fibers from the median 
forebrain bundle join the VPS. The VPS then moves dorsal-
rostrally through the posterior hypothalamic area where 
fiber from the DPS join to form a broad ascending hypo-
thalamic catecholamine system which seems to serve as a 
connection between the dorsomedial and paraventricular 
hypothalamic nuclei. 
(d) The medial forebrain bundle (MFB) 
The MFB is a heterogeneous system containing both 
NE and DA pathways. Caudally, the MFB is formed at the 
meso-diencephalic junction in the area medial to the 
substantia nigra from fibers in the tegmental radiations 
(as previously stated these include fibers from the DTB, 
CTT, and the DPS). The converging fibers give rise to 
the ascending MFB system. Fibers from AlO, the mesolimbic 
DA system, and the AS and A9 cell groups, and substantia 
nigral system, are also present. Lindvall et al. (1974) 
suggested that the substantia nigra DA projection through 
the MFB courses to the limbic cortex. At the rostral 
level of the hypothalamus the DTB joins the MFB. Reflect-
ing their diverse origins the NE fibers of the MFB have 
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widely varying terminations to most brain regions. Those 
fiber tracts are discrete when entering the MFB, remain 
together in this fiber bundle. For additional information 
on the numerous MFB projections see Lindvall and Bjorklund 
(1974). 
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Anesthetic Agents: 
Ketamine 
Ketamine, a phencyclidine derivative, is a short-
acting intravenous or intramuscular anesthetic. Ketamine 
is unusual in the type of anesthesia elicited, and unique 
in that it is the only clinically available drug in its 
class. This agent is considered to be a 11 disassociative 
anesthetic .. and is termed such because it produces a 
state of central detachment from the environment. 
Ketamine is generally a rapid acting anesthetic 
producing a state characterized by profound analgesia, 
catatonia, normal pharyngeal-laryngeal reflexes, normal 
or slightly enhanced skeletal muscle tone, cardio-vascular 
and respiratory stimulation and occasionally a transient, 
minimal, respiratory depression. Autonomic and reflex 
functions are largely unaffected. Airway preservation, 
by maintenance of normal respiratory reflexes, and 
respiratory stimulation permits short procedures to be 
done with relative ease without the need for mechanical 
ventilation (Doubrava and Larson, 1971 ). 
The action of ketamine on the cardiovascular 
system is mediated by three proposed mechanisms; first, 
there is a general stimulation of the central vasomotor 
center; second, a peripheral release of norepinephrine, 
and third, there is evidence that baroreceptor activity 
is decreased, resulting in the increased blood pressure 
and heart rate. 
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The dose of ketamine needed to produce surgical anes-
thesia is related to the developmental stage of the central 
nervous system. This is not only true phylogenetically, 
but is also true in man where a larger dose is needed in 
young children than in adults (Doubrava and Larson, 1971 ). 
In view of the disassociative state produced by this 
anesthetic and its phylogenetic dose relationship, it 
has been presumed that the sensory isolation must occur 
in the association areas of the brain (Doubrava and Larson, 
1971). 
Toxicity of ketamine develops in rats at a dose 
100 X the anesthetic dose, and in humans at approximately 
20 X the anesthetic dose. Toxic doses of ketamine are 
capable of uncoupling the excitation contraction process 
of the cardiac muscle and triggering CNS convulsions 
which can result in death. 
Ketamine is rapidly absorbed and distri-
buted into most body tissues with relatively higher 
concentrations in body fat, liver, lung and brain. It is 
known not to be metabolized in the brain (Cohen and 
Trevor, 1974) and believed mainly to be N-demethylated 
and hydroxylated in the liver to form water soluble 
products. Ninety-one percent of an intravenous ketamine 
dose can be recovered in the urine in the form of 
metabolites. These metabolites are less than l/6th as 
potent as ketamine itself and are believed not to 
contribute to the anesthetic effects (Doubrava and 
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Larson, 1971 ). Repetitive ketamine injections do not 
produce visible tachyphylaxis. A 5-fold increase in 
ketamine metabolism caused by enzyme induction with 
phenobarbital and a 35% prolongation of ketamine's half 
life caused by microsomal enzyme inhibition with SKF-525-A 
have been shown not to affect the duration of anesthesia 
(Cohen and Trevor, 1974). Termination of anesthetic 
action is considered to be due to redistribution, as is 
the case for the short-acting thiobarbiturates. 
The use of ketamine for anesthesia is accompanied 
by a risk of CNS excitation in the post anesthetic period. 
This CNS excitation is termed 11 emergence excitatory 
phenomena 11 and includes restlessness, agitation, 
increased motor activity, crying, screaming, and visual 
hallucinations (Domino et al., 1965; Becsey et al., 
1972). These side effects have added great impetus to 
study the effects of ketamine on central neurotransmitter 
systems. Specifically the catalepsy and hallucinogenic 
effects of this drug have stirred a fortuitous interest 
in these central neuronal systems~ i.e., the cholinergic, 
adrenergic, and serotonergic. Literature on catalepsies 
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and movement disorders continually suggests that these 
defects may be related to a cholinergic-dopaminergic 
imbalance (Arvidsson et al ., 1966; Munkvad et al., 1968; 
Corrodi et al ., 1972). Serotonin and tryptamine have also 
been considered to play a role in catalepsy as demonstrated 
by intracerebral injections (Michaux, 1962; Ernst, 1969). 
Hallucinations and central excitation alone and associated 
with psychotropic drugs have been tentatively linked with 
the noradrenergic and serotonergic systems (Sulser and 
Sanders-Bush, 1971; Weiss and Laties, 1969; Schildkraut 
and Kety, 1967; Snyder et al ., 1970b; Sung et al., 1973). 
With regard to the adrenergic system, several ketamine 
effects have tentatively been identified. 
It has been generally accepted that the adrenergic 
neuronal reuptake system, a high affinity neuronal trans-
port system for NE, functions as the primary means of 
terminating the biologically active neurogenically 
released transmitter at peripheral and central synapses 
(see Iversen, 1971). This type of high affinity system 
is not unique to NE containing neurons. Similar systems 
have been described in brain for neurons containing DA 
(Snyder and Coyle, 1969), gamma-aminobutyric acid (GABA) 
(Iversen and Neal, 1968), and serotonin (5-HT) (Shaskam 
and Snyder, 1970). Several studies have assessed 
ketamine's ability to block these specific reuptake 
systems and therefore potentiate transmitter action. 
smith et al. (1975) demonstrated in vitro in rat cere-
bral cortex tissue that ketamine competitively inhibited 
the high affinity transport system for the uptake of NE 
into adrenergic nerve terminals. Ketamine, in vitro, 
also was found to cause release of stored NE. However, 
ketamine's potency in this respect was estimated at 
l/15 the potency of desmethylimipramine, suggesting 
minor physiologic significance to this action. This 
same group more recently assessed ketamine's in vitro 
ability to block uptake of OA, GABA and 5-HT and com-
pared ketamine's relative potency on each system. Smith 
et al. found ketamine to be most effective in blocking 
5-HT reuptake and l/4 as effective in blocking NE and 
DA reuptake. GABA was least affected (Azzaro and Smith, 
1976). 
Phencyclidine, the parent drug of ketamine, 
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failed to gain clinical usage due to a very high incidence 
of the post anesthetic emergence phenomena. It is of 
interest to note that ketamine, which is considerably less 
potent than phencyclidine in its behavioral effects, is 
also about 100 times less potent than phencyclidine in 
inhibiting synaptosomal NE uptake (Smith et al ., 1975). 
It has now also been demonstrated that phencyclidine 
inhibits DA and 5-HT synaptosomal uptake in approximately 
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the same proportion (Smith et al ., 1975). Even though 
ketamine has been demonstrated to competitively block 
reuptake of these amines, ketamine is not actively 
accumulated in rat brain slices (Cohen and Trevor, 1974). 
Ketamine's effect on central DA metabolism was 
first examined on whole brain samples. These early 
studies report no change in endogenous DA levels following 
ketamine. More recent studies, realizing that endogenous 
levels may be maintained with marked changes in amine 
metabolism (turnover), have also measured DA's major 
metabolite, homovanillic acid (HVA). A rise in this 
metabolite is believed to indicate an increase in central 
DA activity; a fall in this metabolite is taken to mean 
a decrease in central DA activity (Cooper et al., 1974). 
Unfortunately most of the data was derived from whole 
brain studies which limits their value. Biggio et al. 
(1974) found ketamine does not influence whole brain DA 
levels, however, he reported finding a significant 
increase in HVA at 60 minutes post ketamine administration 
and suggested the possibility of an increase in DA turn-
over. Sung et al. (1973), using enzyme inhibition to 
estimate DA turnover, found that 40mg/kg of ketamine 
resulted in a decreased rate of turnover at two hour post 
ketamine administration followed by increased turnover 
four and six hours post administration. The turnover rate 
at six hours post ketamine administration was elevated 
200%. Although the duration of anesthesia was not 
reported, it might be assumed from the given dose and 
animal species that this large increase in turnover 
occurred approximately five hours post anesthesia. The 
relevance of this increase in turnover to anesthesia 
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should be questioned. In 1976, Glisson et al. reported 
endogenous NE and DA levels in rat whole brain and select 
brain regions of rabbit. Again, it was demonstrated that 
no effect of ketamine could be seen in whole brain on 
endogenous amine levels; however, in select areas ketamine 
caused a significant rise in DA levels at 10 and 30 minutes 
post ketamine administration. Ylitalo et al. (1976) 
measured both DA and HVA in rats post ketamine and 
reported significant increases in striatal HVA 15 minutes 
and 1 hour after ketamine administration. These values 
returned to normal 3 hours post drug administration. 
The effects of ketamine on norepinephrine levels 
are less consistent than for dopamine. Norepinephrine 
whole brain levels have been reported to increase (Ylitalo 
et al., 1976), decrease (Sung et al., 1973), and remain 
unchanged (Biggio et al ., 1974) during ketamine anesthesia. 
All experiments were carried out on rats; Ylitalo and 
Biggio used a lOOmg/kg dose while Sung used a 40mg/kg dose; 
in all of these experiments amine levels were examined at 
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approximately the same time periods. 
Investigators have used drugs known to have effects 
on specific central transmitter systems in an attempt to 
delineate relationships between these transmitter systems 
and ketamine. Conflicting results have been found with 
cholinergic and anticholinergic agents. Authier et al. 
(1972) used the anticholinergic agent procyclidine in 
rabbits and found enhanced ketamine-induced catalepsy. 
Hatch (1974) found that atropine, another anticholinergic 
agent, prevented ketamine catalepsy in dogs, however, 
mecamylamine, a ganglionic blocker, was shown to enhance 
ketamine catalepsy. In the case of the serotonergic 
system, Monachon et al. (1972) found in cats that 
methiothepin, an antiserotonergic compound, prevented 
ketamine catalepsy and prolonged ketamine anesthesia. 
With respect to the adrenergic system, pimozide, an antidopa-
minergic compound, was shown by Hatch and Ruch (1974) to 
enhance ketamine catalepsy, and more importantly, antago-
nize ketamine anesthesia. 
Other investigations have attempted to localize 
ketamine's effect on brain by characterizing and localiz-
ing gross changes in electroencephalographic (EEG) 
activity. Ketamine, unlike many other anesthetics, is 
epileptogenic in nature. The increase in EEG activity 
resulting from ketamine's epileptic nature make this form 
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of study more logical than for EEG depressing anes-
thetics. Corssen et al. (1968) first suggested ketamine 
to be a dissociative_ anesthetic based on his findings 
that ketamine electrographically dissociated the 
neocortex from the limbic system, and the thalamocortical 
system from the midbrain reticular system. Also of 
importance is that this group suggested that ketamine 
affected two areas of the brain differentially, the 
cerebral cortex and the limbic system. 
Of the EEG effects induced by ketamine, theta 
activity has been characterized by both Domino et al. 
(1965) and Massopust et al. (1972). The synchronous 
theta activity seen in both the thalamus and the neocortex 
has led Domino et al. and others to speculate that 
ketamine might act on the diffuse thalamic projection 
system at either the thalamic or cortical level. Masso-
pust, on the other hand, has suggested a temporal relation-
ship between theta activity and analgesia from data he 
obtained in rhesus monkey. This group further suggests 
that the beginning of theta activity and analgesia 
correlates well with anesthetics other than ketamine which 
also are potent analgesics (i.e., nitrous oxide and 
cyclopropane). 
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Halothane 
The introduction of halothane into clinical prac-
tice has met with unprecedented success. In an attempt 
to find a non-inflammable volatile anesthetic agent 
Suckling (1957} examined a number of highly stable fluori-
nated hydrocarbons which led to the introduction of 
halothane. 
Halothane is a heavy colorless liquid at room 
temperature. It has a gram molecular weight of 197.39 
and a boiling point of 50.2°C (at one atmospheric pressure}. 
With a vapor pressure of 241 mmHg at 20°C, halothane is 
extremely suitable for vaporization. 
Halothane is a potent nonirritating anesthetic 
characterized by a low post anesthetic incidence of 
complications. Halothane blood solubility coefficient is 
2.3 (blood:gas, partition ratio) resulting in rapid 
induction of anesthesia, as compared to ether. Halothane 
does have a moderate affinity for fat, however, consider-
ing the relatively low blood flow through adipose tissue, 
this affinity becomes important only after prolonged 
periods of anesthesia. 
Halothane has been shown to have profound effects 
on circulation which can lead to moderate or marked 
arterial hypotension. Price (1960} observed decreased 
contractile force, stroke volume and cardiac output with 
halothane-oxygen anesthesia. This myocardial depression 
is directly related to the dose of halothane (Mahaffey 
et al ., 1961; Wenthe et al ., 1962). Depression of the 
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s-A node has been demonstrated by Flacke and Alper (1962). 
Like chloroform, halothane sensitizes the ventricular 
conducting tissues to the actions of catecholamines 
increasing the arrhythmic potential. Vascular smooth 
muscle is also directly affected by halothane. Direct 
vasodilatation has been reported on vascular smooth 
muscle in skeletal muscle and skin (Black and McArdle, 
1962), as well as splanchnic, hepatic and renal vascula-
ture (Epstein et al ., 1962). This vasodilatation is 
accompanied by a diminished blood flow as a result of 
lower systemic pressure. 
It has been suggested by Black and McArdle (1962) 
that halothane blocks the effects of noradrenaline at its 
effector site. In this way halothane interferes with the 
ability of the efferent sympathetic nervous system to 
antagonize a fall in systemic blood pressure. 
Halothane has minimal neuromuscular blocking 
action and therefore at surgical levels must be supple-
mented by specific neuromuscular blocking agents when good 
muscle relaxation is needed. Slight potentiation of the 
non-depolarizing agents and slight antagonism of depola-
rizing agents has been reported (Katz and Gissen, 1967). 
Shivering is common during post anesthesia recovery and 
is attributed to heat loss presumably from cutaneous 
vasodilation. 
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One obvious disadvantage of halothane's clinical 
use for surgery is that it is a relatively poor analgesic 
agent. For this reason, halothane is usually supple-
mented with nitrous oxide. 
To a large extent halothane is eliminated 
unchanged through the lungs. It has been estimated 
that a minimum of 60% of administered halothane is 
eliminated unchanged within 30 hours. Up to 20% is 
metabolized by the liver microsomal enzyme system and 
excreted in the urine (Van Dyke and Chenoweth, 1965). 
The toxicology of halothane stems from halo-
thane's limited metabolism. Hepatic damage as a result 
of halothane anesthesia is believed to result from an 
accumulation of metabolites in the liver. As of yet, 
the toxic metabolite or metabolites have not been 
identified. Halothane has been shown to undergo both 
oxidation and dehalogenation to form trifluoroacetic 
acid and bromide and chloride radicals. Stenger and 
Johnson (1972) have pointed out that animals pre-
treated with phenobarbital, which caused induction of 
microsomal enzymes and therefore increased the fraction 
of halothane metabolized, increased hepatic damage as 
well. More recently, it has been suggested by Van Dyke 
(1978) that in the presence of low oxygen tension the 
pathway of metabolism of halothane is altered resulting 
in the formation of toxic intermediates. This toxicity, 
however, is relevant to chronic rather than acute 
exposure. 
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The relationship of central catecholamine function 
to halothane anesthesia has been studied primarily from 
two directions: (a) halothane's effect on catecholamine 
metabolism; and (b) the effect of pharmacologically 
altered amine metabolism on halothane anesthesia. 
(a) Halothane's effect on central amine metabolism: 
Nikki and co-workers (1971) found halothane to 
increase rat whole brain DA levels and decrease 5-HT 
levels without altering brain NE levels after 30 minutes 
of anesthesia. Anden et al. (1974) found no effect of 
halothane or pentobarbital anesthesia on rat whole brain 
DA metabolism or turnover. This group also investigated 
anesthetic effects on haloperidol-induced increase in DA 
turnover. In rat whole brain, these authors demonstrated 
that pentobarbital but not halothane resulted in a 
decrease in whole brain DA turnover. Ngai et al. (l969a) 
reported that halothane had no effect on NE or DA turnover. 
--
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However, he did report a decrease in the NE rate constant 
with a concomitant increase in endogenous content suggest-
ing altered NE metabolism. Consistent with this finding, 
Li et al. (1964) showed an increase in NE content in the 
heart with halothane anesthesia. Further support comes 
from Persson and Waldeck (1971) who reported a decrease 
in whole brain NE turnover with halothane and Lidbrink et 
al. (1972) who demonstrated a similar effect in the neo-
cortex. 
Ngai et al. (1969b) also investigated halothane•s 
effect on neuronal uptake; unlike ketamine, halothane did 
not significantly alter this process. 
(b) Altered amine metabolism and MAC: 
The minimum alveolar concentration of an anes-
thetic (MAC) necessary to prevent movement in response to 
a painful stimulus in 50% of the subjects tested, has 
proven to be the most readily measurable and accurate 
index of anesthetic potency for inhalation anesthetics 
(Markel and Eger, 1963; Eger et al ., 1963). Alterations 
in potency of an inhalation anesthetics are readily 
measured in terms of altered MAC. 
Sympathominergic drugs have been studied in 
relation to anesthesia for a multiplicity of reasons. 
Of interest to many has been the altered states of 
central nervous system excitation produced by amphetamines, 
catecholamines, depleters (reserpine), and precursor 
therapy (L-DOPA) in relation to anesthesia. 
The effect of both acute and chronic amphetamine 
administration has been evaluated on halothane MAC. 
43 
Acute administration of amphetamine at doses of 0.1 to 1.0 
mg/kg were shown to increase halothane MAC in dogs from 
20% to 100% above controls in a dose related manner. In 
contrast, chronic doses of 5 mg/kg over a seven day period 
produced a 21% decrease in halothane MAC over control 
(Johnston et al ., 1972). Johnston and colleagues (1974), 
in a further attempt to relate these changes to catechola-
mine function, used alpha-methyl-p-tyrosine (AMPT), 
reserpine, and parachlorophenylalanine (PCPA) in conjunc-
tion with amphetamine and determined halothane MAC. They 
found that pretreatment of dogs with either reserpine 
or AMPT greatly reduced the amphetamine precipitated 
increase in halothane MAC, while PCPA, a drug affecting 
serotonin, had no effect, suggesting that catecholamines 
and not serotonin were responsible for the amphetamine-
induced increase in halothane MAC. Reserpine and AMPT, 
catecholamine depleters, were shown to decrease halothane 
MAC when used alone. 
L-Dopa, a precursor for both central adrenergic 
transmitters, DA and NE, when administered results predomi-
nantly in an increase in DA rather than NE (Everett and 
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Brocherding, 1970; Liu et al., 1971) Johnston et al. 
(1975) found that both acute and chronic L-dopa in doses 
of 5 to 25 mg/kg reduced halothane MAC in a dose dependent 
fashion. In view of these results Battista et al. (1973) 
and Johnston (1975) suggested the decrease in halothane 
MAC to be a result of increased central inhibition as a 
consequence of increased DA central content. This group 
further suggests that NE is excitatory in nature centrally 
and therefore an increase in NE centrally results in an 
increased halothane MAC. 
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Nitrous Oxide 
Nitrous oxide (N 2o), one of the first known 
anesthetic agents, was first prepared by Priestly in 1776. 
Not until 1868 did its use become fashionable in clinical 
practice when Andrews combined oxygen with nitrous oxide 
to lay the foundation for its present day use. 
Commercially, nitrous oxide is produced by heating 
ammonium nitrate to a temperature above 245°C, which 
results in two products, N20 and H20. Many of the early 
toxic effects attributed to N20 were shown to be a result 
of ammonia and nitric acid impurities. As a result, 
commercially obtained N20 is carefully processed to a high 
degree of purity and marketed in steel cylinders under 
pressure in a liquid state. 
At room temperature and one atmospheric pressure, 
N2o is a colorless, sweet smelling and nonirritating gas. 
Nitrous oxide is neither inflammable nor explosive but 
will support combustion of other agents, even in the 
absence of oxygen, due to its decomposition at temperatures 
over 450°C to oxygen and nitrogen. 
The blood/gas solubility coefficient of nitrous 
oxide is 0.47. It is rapidly absorbed from the alveoli 
and does not combine chemically within the body and is 
therefore eliminated as rapidly as it is absorbed (Dripps 
et al., 1972). 
Today more general anesthesia techniques are based 
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on the use of nitrous oxide than on that of any other 
single agent (Dripps et al ., 1972). Although N20 is a 
potent analgesic agent, it lacks potency as an anesthetic 
agent. Smith (1971) has estimated that a 101% concentra-
tion would be needed for 1 MAC (as compared to 0.74 for 
halothane), however, 20 volumes %is reported to be 
equivalent to 15 mg of morphine sulphate in analgesic 
effectiveness (Goodman and Gilman, 1975). 
Nitrous oxide has gained wide clinical acceptance 
for current day anesthesia. This can be attributed to 
nitrous oxide's analgesic ability and more importantly 
its capacity to significantly reduce the amount of 
volatile inhalation anesthetic needed to achieve adequate 
levels of anesthesia. Munson et al. (1965) reported that 
a 72 percent alveolar concentration of the N20 reduced 
the MAC of fluroxene anesthetic over 75% (i.e., from 3.4 
to 0.8%). Saidman and Eger (1964), using a 65% concentra-
tion of nitrous oxide, found a 60% reduction in halothane 
MAC. This increases the clinical margin of safety and 
effectively decreases the toxic side effects of these 
potent volatile anesthetic agents. 
As mentioned previously, toxic effects attributed 
to N20 in the early literature have been found to have 
resulted from impurities. Current day manufacturing 
standards have resulted in nitrous oxide gaining the 
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reputation of the least toxic gas anesthetic available 
(Wytie and Churchill-Davidson, 1972). Nitrous oxid~ is 
believed not to be metabolized in vivo. It is eliminated 
through the lung (90%) as well as through the skin (10%). 
various forms of anoxia have been reported in conjunction 
with nitrous oxide use. Two causes have been cited. 
First, when nitrous oxide is used alone in concentrations 
above 80%, required oxygen content of 20% cannot be 
provided. Second, diffusion hypoxia occurs when concen-
trations above 75% of nitrous oxide are used over long 
periods of time (over 90 minutes). During anesthesia 
recovery, rapid elimination of nitrous oxide through the 
lungs can result in decreased oxygen availability if 
inspired oxygen concentration is not kept above 25% (Fink, 
1955; Frumin and Edelist, 1969). 
The amount of research dedicated toward exploring 
the central mechanisms of nitrous oxide has been surpris-
ingly small. This fact may be attributed to nitrous 
oxide's lack of potency. 
Investigation into nitrous oxide's effect on 
monosynaptic and polysynaptic spinal reflex actively has 
shown each to be depressed approximately to the same 
degree (de Jong et al ., 1967; de Jong et al ., 1968b). 
Although research initially suggested the spinal cord as 
a possible site of analgesic action by nitrous oxide, 
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later studies by the same investigators in decerebrate 
cats with intact spinal cords and without the use of an 
anesthetic agent such as halothane, as was used in initial 
experimentation has shown only slight effects on spinal 
cord synaptic transmission (de Jong et al ., 1970). 
The cardiovascular system has been shown to be 
relatively unaffected by nitrous oxide. At high levels 
of nitrous oxide a decrease in ventricular contractile 
force in a sympathectomized preparation was demonstrated 
by Craythorne and Darby (1965). In the nonsympathectomized 
animal a reflex increase in sympathetic tone results with 
nitrous oxide; however, no effect was seen on blood 
pressure, cardiac output, or stroke work. Additional work 
by Lundborg et al. (1966) demonstrated an increase in 
peripheral vascular resistance with nitrous oxide suggest-
ing that nitrous oxide exerts only reflex stimulation of 
the sympathetic nervous system. Recent publications indi-
cate that nitrous oxide, in the presence of halothane, 
results in increased sympathetic activity mediated from 
suprapontine origins. In fact, when cats were sectioned 
midcollicularly, nitrous oxide had a depressant effect 
on peripheral sympathetic activity (Fukunaga and Epstein, 
1973). It is of interest to note that this effect was not 
found when enflurane, another volatile halogenated anes-
thetic, was used (Smith et al ., 1978). 
The relationship of limbic neuronal firing to 
nitrous oxide-oxygen anesthesia has been examined by 
Babb et al. (1975), in seven patients implanted with 
fine wire microelectrodes. Unlike ketamine which has 
been shown to increase limbic neuronal activity, or 
sodium thiopental which has been shown to decrease 
limbic neuronal activity, nitrous oxide was shown to 
have little or no effect on limbic neuronal activity 
as shown by electroencephalographic activity. Impor-
tantly; this suggests that different anesthetics may 
have several different mechanisms of action on synaptic 
transmission in the central nervous system (Babb et al ., 
1975; Galindo, 1975). Babb further suggests that 
thiopental enhances the activity of central inhibitory 
interneurons. 
Nitrous oxide analgesia has been compared ex-
perimentally to analgesia produced by aspirin, alcohol 
and narcotics in an attempt to characterize its nature. 
Unlike aspirin and alcohol, nitrous oxide resembles 
pharmacologically the opiates in inhibition of pain. 
Nitrous oxide analgesia is reversible in a dose related 
fashion (5-30 mg/kg) by naloxone; its euphoric action 
can also mimic narcotic euphoric effects (Berkowitz et 
al., 1977). Berkowitz and co-workers have suggested 
three important areas of research needed to help clarify 
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mechanisms of analgesia: (1) Alterations in metabolism 
of NE, DA or 5-HT; (2) Alterations of receptors or post 
synaptic events in relation to these or other transmitter 
systems; (3) Release mechanisms for the endogenous opiate 
like substances, endorphine and enkephalin, need to be 
established in relation to the stated transmitter systems. 
CHAPTER II 
METHODS 
Animals 
Specific animal needs of the research involved in 
this dissertation required: (1) that the animals be easy 
to handle, (2) that they have large lateral ventricles 
adequate in size to facilitate intraventricular administra-
tion of 14c-tyrosine necessary for isotopic determination 
of catecholamine turnover, (3) that the brain size be 
sufficiently large so that the catecholamines could be 
assayed on brain regions of a single animal in order to 
avoid the increased error encountered when brain parts are 
pooled, (4) and lastly, for administration of the volatile 
inhalation anesthetics, animals large enough for tracheal 
intubation were needed. To meet these specific require-
ments, adult male albino New Zealand rabbits were chosen. 
Male animals were used exclusively to prevent possible 
estrus effects on the experimental results. Animals were 
obtained from a single breeding source, as it has been 
shown that turnover levels can be significantly affected 
when different sources are used (Costa, E., 1971 ). All 
animals were housed in individual rabbit cages located 
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-within the Animal Research Facility. These facilities 
are maintained at 22 degrees Centigrade with a 12 hour 
alternating light-dark cycle. Food and water was 
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provided to the animals ad lib. All animals were housed 
in these conditions for 2 .weeks prior to use. The brain 
areas used in this study were the mesencephalon, thalamus, 
hypothalamus, and cortex. These areas were chosen 
because: (1) they have sufficient content of the amines 
under study to prevent the necessity of brain part pooling, 
(2) they are major anatomical subsections of the brain, 
and (3) for literature comparison, these areas are fre-
quently studied. 
--
Basic Turnover Techniques 
In establishing the turnover techniques to be 
used in this dissertation, many turnover methods were 
considered (e.g., Isotopic: Labeling of stores with 
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either labeled precursor or labeled transmitter; Noniso-
topic: Inhibition of biosynthesis or measuring end product 
formation (Costa and Neff, 1970)). After an in-depth 
evaluation of all methods available, the isotopic trace 
precursor method was found to be the most reliable. 
Basic to this measure of turnover is the metabolic 
pathway of endogenous catecholamine synthesis (cf. Figure 
#1). L-tyrosine, the precursor to both DA and NE, enters 
the central nervous system (CNS) by transversing the 
blood-brain barrier. Once in the nerve cell, L-tyrosine 
is converted to L-3,4-dihydroxyphenylalanine (L-dopa) 
by the enzyme tyrosine hydroxylase. This conversion of 
tyrosine to L-dopa is considered to be the rate limiting 
process which controls the amount of transmitter synthe-
sized by the nerve cell, L-dopa is then converted to 
dopamine and/or norepinephrine depending on whether the 
cell is dopaminergic or noradrenergic in nature. During 
11 steady state 11 neuronal activity, the amount of NE or DA 
synthesized is considered to be equal to that degraded 
(Costa, 1971), thus a constant endogenous 1 evel of 
neurotransmitter is maintained. It is important to 
r 
Enzymes: 
Co factors: 
Figure 1 
14c PULSE INTRAVENTRICULAR TRACE PRECURSOR TURNOVER 
tyrosine 
hydroxylase 
(Rate Limiting) 
I 
aromatic L-amino acid 
decarboxylase 
L-TYROSINE ,---------- L-DOPA* DOPAMINE 
14c-L-TYROSINE 
Fe++, 0 
t 'd. 2 p en 1 ne 
Intraventricular 
injection 
B6 
14c-L-DOPA 
In vivo Synthesis 
*L-DOPA = L-3,4 dihydroxyphenylalanine 
14C-DOPAMINE 
hydroxylase 
02, cu++ 
ascorbate 
NOREPINEPHRINE 
--,• 
14C-NOREPINEPHRINE 
CJ1 
~ 
, 
55 
Figure #1 Diagram of the biosynthesis of dopamine and 
norepinephrine in the central nervous system. Tyrosine, 
which is permeable to the blood brain barrier, is sup-
plied to the brain from the blood. Radioactively labeled 
tyrosine ( 14 c-L~Tyrosine) is introduced intraventricularly 
and is subsequently metabolized in vivo to labeled dopamine 
and norepinephrine and to their respective metabolites 
parallel to the non-labeled endogenous amines. 
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understand that basic to the concept of turnover is the 
primary assumption that the amount of transmitter released 
(neuronal activity) is proportional to the amount degraded. 
Since the amount of transmitter formed is equal to that 
degraded, it has been ascertained that both synthesis and 
degradation are proportional to transmitter release. 
These premises are the foundation upon which the concept 
of turnover has been established (Costa, 1971; Costa and 
Neff, 1970; Cooper et al., 1974). As described, turnover 
is an estimate of neuronal activity, is based on steady 
state kinetics, and is calculated from the rate of 
synthesis or degradation of the transmitter under study. 
Preliminary Studies: 
Initially several preliminary studies were 
undertaken to establish dopamine and norepinephrine 
turnover methodologies which would be of sufficient sensi-
tivity so that individual brain parts could be used 
without brain pooling and to be able to determine dopa-
mine and norepinephrine turnover in four brain regions 
simultaneously. After careful screening, an isotopic 
precursor method was chosen using labeled L-tyrosine for 
the precursor (used because it precedes the rate limiting 
enzymatic step that controls the synthesis rate). 
Two commonly used isotopically labeled tyrosine 
forms are available, 3H and 14c. 3H-tyrosine has a higher 
--
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specific activity than 14c-tyrosine, however, the 3H atoms 
easily exchange with H+ atoms particularly at a low pH. 
This makes the 3H labeled form unreliable for use in 
these experiments which required acid extraction. The 
14c-L-tyrosine form was found to be stable at low pH and 
used throughout these experiments (483 mCi/mmol, Amersham-
Searle Co.). 
The intraventricular injection technique used was 
previously described by Glisson (1971). Dye and isotopic 
distribution using the intraventricular injection route 
showed an acceptable distribution to all brain areas 
... 
under study and was identical to that reported by Glisson 
(1971). 
It should be noted that initially the caudate 
nucleus was to be included in this study, however, it was 
found that this brain area, which is in juxtaposition to 
the isotopic injection site, had an unacceptable differ-
ence in isotope concentration between the left and right 
sides. The magnitude of such unequal isotopic distribu-
tion for this particular area would result in an erroneous 
determination. 
Based upon results of preliminary trials the 
following procedure for isotopic intraventricular injec-
tion was adopted: Four hours before the turnover 
experiment, each animal was gently restrained and the hair 
clipped from the top of the head. Lidocaine (1%) was 
injected intradermally into the scalp (0.25cc). The 
analgesic field was tested by a pin prick; in the 
absence of analgesia the animals blink. After the loss 
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of pain sensation midline longitudinal incision was made 
through the scalp exposing the skull. Bone wax was 
applied to the skull to stop any bleeding from the bone. 
The coronal and sagital sutures were visualized. Using 
dividers a point 4.0 mm caudal to the coronal suture and 
4.5 mm lateral to the sagital suture was identified and 
marked. A small hole was then made using a blunted 18 
gauge needle by gentle hand rotation. Special care was 
taken never to penetrate the dura mater. Bone wax was 
then applied to seal the hole until tim~ of the intra-
ventricular injection. The surgical procedure itself 
produced no signs rif stress during or after establishing 
the intraventricular injection site. The animals were 
then left undisturbed until the start of the experiment. 
Intraventricular injections were made through the 
injection site using a 250 ~1 syringe fitted with a blunt 
27 gauge stainless steel needle 6 mm in length. Using 
gentle pressure, two and one half ~Ci of 14c-L-tyrosine 
was delivered slowly in a 50 ~1 volume. Once the isotope 
was delivered the hole was immediately resealed with bone 
wax. All injections were visually confirmed for 
·r~ 
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intraventricular placement during dissection of the brain. 
This type of injection is referred to as delivering a 
11 pulse dose. 11 The amount of L-tyrosine injected into each 
rabbit was 883 ng. The quantity of isotopic tyrosine 
injected in proportion to the whole brain content of 
tyrosine must be minute so that the endogenous tyrosine 
pool is not significantly altered. This small amount is 
frequently referred to as a 11 trace dose. 11 Generally the 
above described technique is referred to as an isotopic 
~lse intraventricular trace precursor technique (Costa, 
1971). 
14
c-L-tyrosine enters the metabolic scheme as is 
shown in figure #1. The rate of synthesis of 14 c-L-DOPA 
from 14c-L-tyrosine parallels that of endogenous L-DOPA 
from endogenous L-tyrosine. The labeled transmitter 
synthesized is stored and released from the granular 
pool as is the endogenous transmitter (Costa, 1971; 
Costa and Neff, 1970). The rate of synthesis, or 
degradation, can be determined by measuring the content 
of labeled transmitter in whole or brain parts at 
different time periods (Brodie et al ., 1966; and figure 
#2). For these determinations, specific portions of the 
synthesis or degradation curves are used. The degradation 
slope (run off slope) is best suited for turnover de-
termination due to its long stable exponential decay. 
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Diagramatic Representation of a Typical Exponential 
Isotopic Catecholamine Run Off Slope 
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i: 
-Figure #2 Diagramatic representation of a typical 
exponential isotopic catecholamine run off slope as 
determined by sampling the isotopically labeled 
dopamine or norepinephrine in brain regions at the 
four designated time coordinates. When disintegrations 
per minute I ~ram (DPM/Gm) are plotted against time 
an exponential function is found (above). When the 
DPM/Gm values are converted to natural logarithm and 
plotted, a straight line function is derived (below). 
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Preliminary studies demonstrated that run off slopes 
varied in time with different brain regions. Based upon 
the results, four time periods were chosen which allowed 
for the simultaneous turnover measurement of dopamine and 
norepinephrine in the four brain areas used. These time 
coordinates were 40, 55, 90, 105 minutes. 
Turnover Calculations: 
Calculation of turnover is based on two factors: 
(1) the "rate constant" as determined by the run off 
slope and (2) the level of endogenous transmitter. The 
rate constant is defined as the fraction of the neuro-
transmitter pool that is lost per unit time and is 
frequently referred to as the "fractional rate constant" 
(for additional information see Brodie et al ., 1966; Costa, 
1971). Once the rate constant and endogenous amine level 
have been determined, turnover is then calculated as the 
product of the rate constant times the endogenous level. 
The limiting problems concerning measurement of 
catecholamine turnover in vivo involve: (1) establishment 
of steady state conditions, (2) the number of time points 
that can be measured in a single animal, (3) unknown 
cytological factors, (4) enzyme and substrate controlling 
mechanisms are not fully understood, to name a few. A 
comprehensive discussion of these and other limitations 
--
can be found in articles by Costa (1971) and Costa and 
Neff (1970). 
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Specific Methodologies 
The specific methodologies used in this disserta-
tion to measure dopamine and norepinephrine turnover in 
the various brain areas are as follows. All experiments 
were started at approximately 9:30 a.m. to minimize 
chronobiological variation. A total of 52 animals was 
used to establish the awake control data. Four animals 
were used for each run, where one animal was used for each 
time period. Awake control subgroups were staggered 
between each anesthetic series to help control for 
seasonal variation. In each anesthetic group sixteen 
animals were used, four at each time period. 
Tissue Samples: 
Animals were sacrificed by decapitation. The 
brains were removed rapidly, rinsed well with saline to 
remove excess isotope and placed on an ice cold petri 
dish for dissection. Surface blood vessels and connective 
tissue were removed. The left and right cerebral hemi-
spheres were separated. A cut was made through the left 
and right cerebral peduncles, freeing the left and right 
hemispheres. With careful teasing, the hippocampus was 
removed exposing the caudate nucleus from head to tail. 
Using a pair of toothed iris forceps, the caudate nucleus 
was teased away from the ventricular wall. A cut just 
lateral to the internal capsule was made to remove the 
lenticular nuclei. The remaining tissue was considered 
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as cortex. Next, the midbrain-diencephalon region was 
obtained by transecting the lower brain stem on a line 
from the caudal end of the inferior colliculus to the 
rostral end of the pons, thereby isolating the midbrain-
diencephalon from the rest of the brain stem. The 
midbrain was separated from the diencephalon by a trans-
verse cut. The diencephalon portion was cut transversely 
to facilitate dissection of the thalamus and hypothalamus. 
A transverse section was made separating the dorsal 
thalamus from the more ventral hypothalamus. These 
dissections were easily made and identical areas were 
always removed as demonstrated by the consistent brain 
part weights (See Appendix A). 
Catecholamine extraction: 
Immediately following removal, each tissue was 
weighed and placed in a 15 ml ground glass homogenizing 
tube containing 6 ml ice cold 0.4 N perchloric acid, 0.02% 
ascorbic acid and 0.2% EDTA. The tissue was thoroughly 
homogenized and poured into a 15 ml thick walled conical 
centrifuge tube stored on ice. An additional 2 ml of 
0.4 N perchloric acid were added to the homogenizing 
vessel as a wash and then transferred to the centrifuge 
tube. The tubes were placed in a r~frigerated centrifuge 
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held at 0°C and centrifuged for 20 minutes at 3200 x g. 
Following centrifugation, the supernatant was filtered 
using Whatman #1 filter paper. The pellet was resuspended 
in 2 ml of ice cold 0.4 N perchloric acid and centrifuged 
for reextraction. The supernatant was filtered and 
combined with the original supernatant. The tubes were 
sealed and stored frozen (-25°C) until catecholamine 
separation by column chromatography (Glisson, 1971). 
Column preparation: 
The column assemblies were adapted from 1.0 ml 
disposable syringes. It was necessary that the internal 
diameter of the syringe barrel be 4.2 - 4.5 mm. The upper 
lip of the syringe was cut off and a 2 em piece of tygon 
tubing affixed to the top of the syringe barrel in such 
a way that one centimeter of tubing extended above the 
top of the barrel (Glisson, 1971). This 11 COlumn assembly., 
was then submerged in a beaker containing distilled water. 
It was necessary that the actual packing of the column 
with resin be done under airtight conditions, as air 
bubbles will disrupt the uniform packing of the resin. 
Air bubbles were removed from the empty column assembly 
by inserting a stirring rod inside the column and working 
it up and down a few times. With the column completely 
filled with water, a small ball of Pyrex glass wool was 
inserted into the column and forced to the tip with a 
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stirring rod. This piece of glass wool serves to trap the 
resin within the column. A G 50w X 4 200-400 mesh resin 
cleaned and cycled to the H+ form was suspended in 0.01 M 
phosphate buffer and 0.1% EDTA and placed in a 2ml pipet. 
The tip of the filled pipet was inserted under water into 
the tygon tubing attached to the top of the column. The 
resin was then allowed to flow into the column. After 
the resin bed had settled to a height of 50mm, another 
ball of Pyrex glass wool was inserted into the top of the 
column. The freshly packed columns were then mounted onto 
the column board. 
The column board consisted of 20ml graduated glass 
syringes mounted through a horizontal board attached to 
ring stands. A plastic 3 way stopcock was attached to the 
tip of this syringe. To the side of this syringe, a 20ml 
syringe barrel was mounted in a similar fashion. This 
barrel served as a reservoir through which the tissue 
extract and other reagents could be added to the column. 
The reservoir and syringe were connected through a series 
of plastic stopcocks. On the open end of the stopcock 
attached to the glass syringe, a plastic fitting was 
placed. The fitting allowed for an air-tight seal to be 
made between the tygon tubing on the resin column and the 
stopcock on the glass syringe. The fitting was made by 
removing the metal insert of a disposable needle and using 
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the upper plastic portion as the fitting. Prior to the 
attachment of the freshly packed resin column, distilled 
water was added to the reservoir and drawn through the 
stopcock assembly into the syringe to remove any air from 
the system. With the distilled water slowly dripping 
through the stopcock, the resin column was seated tightly 
on to the stopcock fitting. The column was mounted in 
such a way as to allow for liquids to be drawn into the 
glass syringe from the reservoir and then to flow through 
the resin column. With the resin column mounted on the 
column assembly, the resin was then cycled from the H+ 
form to the Na+ form by passing 20 ml O.lM sodium phos-
phate buffer containing 0.1% EDTA at pH 6.5 through the 
resin column at a flow rate of one drop every 10 seconds 
(.3mls/min)(Glisson, 1971 ). After the buffer had passed 
through the column the pH of the effluent was checked. 
A pH of 6.5 indicated that the column was cycled and 
ready to receive the tissue extract. 
Catecholamine Ion Exchange Column Chromatography: 
Before adding the tissue extract to the column, 
the pH was adjusted to 6.5 using 10 N potassium carbonate. 
A digital pH meter, magnetic stirrer and an automatic 
buret were used. At pH 6.5, potassium perchlorate 
precipitates out of the neutralized extract. Placing the 
neutralized samples into a refrigerator for 10 minutes 
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increases the precipitation rate. Following cooling, the 
extract was centrifuged at 1500 g for 10 minutes to pack 
the precipitant. The supernatant was poured into the 
reservoir of a column assembly. The extract was drawn 
into the glass syringe and allowed to flow through the 
resin at a rate of one drop every 10 seconds. After the 
extract passed through the column, the resin was washed 
with 40 mls of distilled water. The flow rate for the 
water wash was twice as fast as that of the tissue extract. 
Care must be taken in handling the water wash as well as 
all column effluents, as the water will contain consider-
14 
able amounts of C products washed from the resin. 
Following the wash, 1 N hydrochloric acid was added to 
the reservoir. During the elution and fractionation of 
the norepinephrine and dopamine (isotopic and endogenous), 
the flow rate for the hydrochloric acid (HCl) was again 
controlled at 1 drop every 10 seconds. The first 3.5 ml 
HCl passed through the column was collected and discarded 
by appropriate isotopic waste procedure. The next 6 mls 
of acid passed through the column containing the norepine-
phrine were collected in small shell vials that had been 
washed and rinsed in distilled water. An additional 13 ml 
HCl fraction was collected and contained the dopamine. 
All vials were sealed and frozen at -25° C until 
samples were thawed for further processing. 
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Catecholamine quantification: 
Before either norepinephrine or dopamine can be 
quantitatively measured, they must be converted to their 
respective fluorophores. As fluorophores dopamine and 
norepinephrine can be measured using a spectrophotofluoro-
meter. Since norepinephrine and dopamine are converted 
at different optimum pH•s to two different fluorophores, 
the method is highly specific for each compound (Carlsson 
and Lindqvist, 1962; Carlson and Waldeck, 1958). 
The conversion scheme for norepinephrine as 
modified from Glisson (1971) is shown in table #1. Upon 
completion of the chemical procedure shown in table #1, 
the samples were poured into reading tubes and read in an 
AMINCO spectrophotofluorometer equipped with an ellip-
soidal mirror condensing system at 400 nM excitation and 
505 nM emission wavelengths. The fluorophore was found 
to be stable for one half hour. The samples were read 
within this time period. Spectral curves were plotted to 
insure sample purity. Maximum sensitivity of these 
methods was found to be 500 picogram (NE). Calculation 
of endogenous norepinephrine was done using the mathemati-
cal equation as shown in table #2. 
For dopamine, it was necessary to develop new 
assay techniques to be able to measure the concentrations 
in a single brain region. This was accomplished in two I 
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TABLE #1 
Conversion of hrinolutine 
Reagent Standards Faded Internal 
1X 2X Blank Sample Standard 
H 20 3.8 3.7 1.4 1.4 1.3 
PO 4 
I 
Buffer 
0 . 1 M 
6. 5 pH 0. 5 0. 5 0. 5 0. 5 0. 5 I 
NE Std. 
1 ug/ml 0.1 0. 2 0.1 
Neutral 
Sample 
Eluate 2. 5 2.5 2. 5 
0.5 % 
Zinc 
Sulphate . 05 . 05 . 05 . 0 5 .05 
0.25 % 
K3Fe(CN) 6 . 05 . 05 . 0 5 .05 .05 
Hait Five ~Hnutes 
5N NaOH + 
2% Ascorbic 
Acid . 5 0. 5 0.5 0. 5 
5N NaOH .45 
Wait Ten Minutes 
2% Ascorbic 
Acid .05 
--
Table #1 (continued) 
Read samples within 30 minutes in a spectrophotofluoro-
meter at 400/505 nM. 
All units are ml. 
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Table #1 The chemical scheme for the conversion of 
norepinephrine to norepinephrinochrome and then to 
norepinephrinolutine. This conversion is specific 
for norepinephrine (cf. text) and results in a fluor-
escent molecule that can be assayed quantitatively 
in a spectrofluorometer. 
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TABLE #2 
Calculation of Endogenous NE and DA 
Tissue Catecholamine Concentration (ug/g) = 
(Samp.FR. - T.Blk.FR.) Std C (Std.FR. - RB.FR.) x ... one. X Vol .Samp. Fct.Samp. 
Where: 
Std.FR. 
RB.FR. 
Samp.FR. 
T. Bl k. FR. 
Std.Conc. 
Vol .Samp. 
Fct.Samp. 
RF 
BPW 
= Standard fluorometric reading 
= Reagent blank fluorometric reading 
= Sample fluorometric reading 
= Tissue blank fluorometric reading 
= Standard concentration in ug. 
= The total volume of sample. For the NE sample this 
is the 6 mls. column eluate plus the K2co 3volume 
used to neutralize it to 6.5 pH. For DA this would 
be the 1 ml. volume used to dissolve the freeze dried 
column extract. 
= The fractional amount (in mls.) of the Vol .Samp. used 
in the determination. 
= The recovery fraction as determined by the 
11 recovery standards 11 for that particular run (ug 
recovered/concentration added). 
= The brain part weight in grams wet weight. 
--
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steps. First, (a) the 13 mllN HCl column elution volume 
containing the dopamine was reduced in volume to concen-
trate the eluate. The second procedure (b) used to 
improve dopamine sensitivity was to develop a micro scheme 
for fluorophore conversion. Each will be discussed 
separately. 
(a) A freeze drying technique was employed to 
reduce the 13 ml dopamine samples to dryness. Dopamine was 
found to be chemically stable throughout this process. 
The freeze dryer was obtained from the Virtis Company 
Model #10-010 and was equipped with a 150 liter/min vacuum 
pump and a Mcleod gauge, so that an accurate measure of 
internal vacuum could be determined. 
Freeze drying was accomplished by the following 
procedure. The instrument was started and allowed to 
equilibrate to a temperature of -65° centigrade and an 
internal vacuum of 0.05 uM Hg. An acetone-dry ice bath 
was prepared. Each dopamine sample eluate was placed in 
a lOOml round bottom freeze-drying flask that had been 
previously cleaned with concentrated potassium hydroxide 
solution, and finally repeatedly rinsed with distilled 
water. Each sample was shell-frozen by gentle rotation 
in the bath until solidly frozen. Samples were placed 
on the freeze dryer and the vacuum allowed to reequilibrate 
.I 
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to 0.05 uMHg. between sample placement. This procedure 
was repeated until all samples were frozen and placed on 
the freeze dryer. A maximum of 12 DA samples could be run 
at any one time. 
An additional freeze dryer recovery control was 
added at this point of processing. Since dopamine under-
went both exchange column chromatography separation and 
freeze drying, a known standard was introduced prior to 
freeze drying so that recovery could be monitored for 
both operations. To this end two standards were prepared 
for each run (i.e., 2 standards with 10 samples) by adding 
~ 
a known concentration of dopamine to 13 mls of 1 N HCl. 
Freeze dried dopamine recovery was demonstrated both 
fluorometrically and isotopically to be 90% + 5 down to 
lOng. It took 12 hours to reduce all samples to dryness. 
The samples were removed from the freeze dryer and 1 ml 
of 0.01 N HCl was added to each flask to redissolve the 
crystalline dopamine. One third of the HCl was placed in 
a scintillation vial with 10 ml of HandiflourR. The vial 
was placed in a Packard Tri-Carb scintillation counter 
and the radioactivity measured. The remaining 0.66ml was 
used for the OA fluorophore conversion. 
(b) The dopamine fluorophore quantification method 
was adapted from the trihydroxy indole method of Carlsson 
Jl 
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and Waldeck (1958). The method was modified to reduce 
the total reaction volume so that the concentration of the 
dopamine fluorophore would be greater per unit volume. 
During preliminary studies, it was determined that 
the total reaction volume could be successfully reduced 
from 6mls to 1.22 mls resulting in a 4.9 fold increase in 
fluorophore concentration per unit volume. The chemical 
conversion scheme is shown in table #3. 
After cooling the samples for one hour they were 
poured into reading tubes and read in a spectrophoto-
fluorometer at 330 nM excitation and 380 nM emission, 
wavelengths uncorrected. Spectral scans were plotted to 
confirm the existence of uncontaminated dopamine in the 
sample. Calculation of endogeno~s dopamine was done using 
the mathematical equation as shown in table #2. 
In effect, freeze drying and the micro-volume 
fluorophore conversion increased the method•s sensitivity 
by 65 X. It should be noted that accompanying this 
increase in sensitivity was an accompanying increase in 
tissue blank fluorescence. To this end extreme care must 
be taken in cleaning and rinsing all glassware used and 
resin should be carefully cleaned by cycling to minimize 
blank fluorescence. Maximum final sensitivity of the 
dopamine methods was determined to be lng. 
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Reagent 
Citrate 
Phosphate 
Buffer 
DA Std. 
100 ng/ml 
DA Std. 
1 ug/ml 
Freeze 
Dried 
Sample 
Na 2so 3 
+ ~aOR 
Iodided 
Solution 
5N Acetic 
Acid 
TABLE #3 
Conversion of Dopamine to Dopaminolutine 
(Fluorometric Conversion) 
Standards 
1 X 2X 4X 
0.45 0.2 0.6 
0.1 0.1 0.1 
0.25 0. 5 
0 . 1 
Reagent 
Blank 
0.7 
0 . 1 
Sample 
0.4 
0 . 1 
0. 3 
Boil Blank ONLY for Twenty Minutes 
0.02 0.02 0.02 0.02 0.02 
Wait Five Minutes 
0 . 1 0. 1 0. 1 0. 1 0. 1 
Wait Five Minutes 
0.3 0. 3 0.3 0. 3 0. 3 
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Blank 
0.4 
0 . 1 
0. 3 
0. 1 
0.02 
0.3 
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Table #3 (continued) 
Boil for Thirty Minutes 
Cool for Thirty Minutes (Read 330/380nM) 
All units are ml. 
Table #3 The chemical scheme to convert dopamine to 
dopaminochrome and on to dopaminolutine. Dopaminolutine 
is fluorescent and can be quantified with a spectra-
fluorometer. This procedure is specific for dopamine 
in that any possible norepinephrine contamination will 
80 
not affect the amount of fluorescence produced (cf. text). 
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Calculation of the Isotopic Catecholamine Run Off Slope: 
1) Determination of NE and DA disintegration per 
minute (DPM) per gram of tissue (i.e., OPM/G): The amount 
of 14 c NE and DA produced in vivo was determined by 
measuring individually the NE and OA counts (CPM) per 
sample as formulated in table #4. 
2) Plotting and regression analysis of the iso-
topic data: Eight turnover plots can then be generated 
of 16 points each from the 128 (8 X 16) separate OPM/G 
determinations. Each plot is constructed separately. 
First, the log DPM/G were determined (either natural or 
common log may be used; however, if common log is used 
a correction factor is necessary), and the corresponding 
time coordinates converted to fractions of hours. With 
the abscissa as time in hours and the ordinate as log 
DPM/G, each point can then be appropriately plotted. A 
sample plot is shown in figure #2. Regression analysis 
was performed on the isotopic data to determine the 
slope (i.e., the run off slope or rate constant) and its 
respective correlation coefficient (r). The correlation 
coefficient indicates the probability of fit of the data 
points. Only regression lines that demonstrated a 
significant fit of p <.05 were used. The regression lines 
were then plotted and the slope determined. The calculated 
slope or run off slope is the rate at which the 14 c trans-
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TABLE #4 
Calculation of the Isotopic Catecholamine Run Off Slope 
Where: 
CPM 
BG 
Vol. Samp. 
BPW 
CE 
Fct. Samp. 
Col. R. 
DPM/G = (CPM-BG) X Vol. Samp. BPM X CE X Fct. Samp. X Col. R. 
= Counts per minute for each sample as counted in a 
refrigerated Tri-Carb liquid scintillation 
spectometer. 
= Background counts. 
= The total volume of sample. For the NE sample this 
is the 6ml column eluate before neutralization. 
For DA this would be the lml volume used to dissolve 
the freeze dried column extract. 
= Brain part weight in grams (wet weight). 
= Counting efficiency as determined by a sealed 
14c OA and 14c NE standard which was counted 
simultaneously with each set of samples. 
= The fractional amount (in mls) of the Vol. Samp. 
used for scintillation counting. For OA Fct. Samp. 
= 0.3mls, for NE Fct. Samp. = l.Oml. 
= Column recovery 
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mitter is leaving the nerve terminal under study. Once 
both the endogenous level and the run off slope have 
' been determined, the turnover rate of NE and DA can be 
calculated as their product (Brodie et al ., 1966). 
Computer Calculation of Data: 
Data handling initially presented itself as a 
problem. The large amount of data, for example for 
control sets there were 320 samples and each sample had 
16 data bits (i.e., volume, Fluorometer reading, etc.) 
totalling over 5,000 numbers, had to be recorded and entered 
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into the appropriate phase of calculation. Data recording 
and repetitive calculations, however, lends itself readily 
to computer adaptation. To facilitate data handling a 
computer based storage, calculation, and statistical 
analysis system was developed. The system was created 
to be interactive (i.e., run from a computer based time 
sharing terminal). The computer language used was Pl-1. 
All programs were designed to both store and output all 
data entered and values calculated so that errors due 
to manual handling of the data were eliminated. All 
programs were system tested for accuracy by at least two 
different people on separate occasions. 
All data was stored on a disk file system with 
a back-up tape system to prevent loss of data in the event 
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of a computer breakdown. Statistical programs used in 
this dissertation were adapted from existing documented 
computer statistical systems. Using the adapted programs, 
determination of mean, standard deviation, standard error, 
variance, range, maximum, minimum, t-test comparison, 
plotting, regression analysis, and s)ope comparison by 
covariance analysis could be carried out (Snedecor and 
Cochran, 1967, pp. 421-425). 
Monitoring Techniques: (cf appendix B for values) 
It was necessary to insure "normal physiological 
functionu (cf. below) in all experimental animals. "Normal 
physiological function" in these experiments is taken to 
mean stable blood chemistries, core temperature, and blood 
pressure throughout the experimental procedures. All 
experimental animals were equipped with an indwelling 
arterial and venous femoral catheter. To avoid pain to 
the animals, these catheters ~ere positioned through a 
small incision, one half inch in length, following local 
infiltration of 1% lidocaine (0.25 ml ). 
One ml blood samples were drawn at regular 
intervals for blood chemical analysis. A model 165 
Corning Blood gas analyzer was used to determine blood 
pH, Pao 2 , Paco 2 , HC0 3 , and bases of excess by standardized 
procedures. An average of six arterial blood samples were 
drawn per animal 20 minutes apart or as needed. In the 
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halothane experiments a 100 ul capillary tube was filled 
with arterial blood and sealed immediately upon acquisi-
tion of the lml sample for subsequent determination of 
blood halothane (cf. Lowe, 1964). 
Blood pressure was monitored via the femoral 
arterial cannula connected to a Hewlett Packard pressure 
transducer and displayed on a recording polygraph. Blood 
pressure and heart rate were recorded just prior to each 
blood sample. Both systolic and diastolic pressures were 
obtained. Where necessary mean blood pressure is con-
sidered to be l/3 X pulse pressure plus diastolic pressure 
where pulse pressure is equal to systolic pressure minus 
diastolic pressure. 
Core body temperature was approximated by monitor-
ing rectal temperature continuously with the aid of Yellow 
Springs Telethermometer. It was found that normal body 
temperature (39°C) could be maintained easily in anesthe-
tized animals by maintaining a 27°C room temperature. An 
auxiliary heating pad was seldom used. 
Volatile and Gaseous Anesthetic Delivery 
System for Halothane and Nitrous Oxide: 
To deliver halothane, a volatile anesthetic, and 
nitrous oxide (N 2o), a gaseous anesthetic, to the rabbits 
under study, it was necessary to create an anesthetic 
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delivery system to maintain consistent blood anesthetic 
levels in animals from experiment to experiment. Spon-
taneous breathing anesthesia delivery systems were disre-
garded. A delivery system where ventilation and delivered 
anesthetic concentration could be controlled minute to 
minute was decided upon. 
For this purpose, a semi-closed pediatric anes-
thetic circuit was chosen and modified to allow for 
ventilation of two rabbits simultaneously. There are two 
distinct advantages of this system: (1) continuous 
control of physiologic blood gases and anesthetic con-
centration, (2) with a semi-closed system and a proper 
evacuation system, there is no escape of the anesthetic 
gases into the room to present a health hazard to 
laboratory personnel (OSHA Standards). 
The delivery system was comprised of five major 
on line components (figure #3). (a) An Ohio Medical 
Metamatic veterinary ventilator was used to circulate 
oxygen and anesthetic through the system and ventilate 
the animals. This ventilator is designed for anesthetic 
gas delivery and allows for a wide variety of ventilation 
patterns either volume or pressure limited. (b) A series 
of flow gauges and valves were used to regulate gas flow 
and mixture. A Foregger system was used. (c) A halothane 
vaporizer (Foregger Fluomatatic) which compensates for gas 
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ANESTHESIA CIRCUIT 
(c) 
FIGURE # 3 
Figure #3 Diagram of the anesthesia circuit used in 
conjunction with the nitrous oxide, halothane, and 
halothane - nitrous oxide combination studies. Shown: 
(a) an Ohio Medical Metamatic Ventilator, (b) a series 
of flow gauges, (c) a halothane vaporizer, (d) a carbon 
dioxide absorber and (e) corrugated anesthetic tubing 
equiped with two 11 0'ne way 11 valves. 
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flow, ambient temperature, and barometric pressure to 
deliver the precise concentration desired was used to 
deliver halothane. (d) A carbon dioxide (C0 2 ) soda lime 
absorber was used to remove expired co 2 . Finally, (e) 
disposable corrugated anesthetic tubing and two one way 
valves were used to complete the circuit and maintain a 
"one way" flow and screw clamps were interposed between 
the animals and the circuit to adjust for difference in 
animal compliance. 
Tracheal Intubation: 
Tracheal intubation in the rabbit is difficult 
but can be accomplished consistently and nontraumatically 
once the skill has been refined. First the animals were 
pre-oxygenated for 5 minutes with 100% o2 via an animal 
mask. The ventilatory system was checked for leaks and 
primed with 100% 02 during this period. A cuffed endo-
tracheal tube of appropriate size was chosen. It was 
found in this study that for every 1 kg of body weight, 
1 mm in tube size was needed. The endotracheal tube was 
placed on an introducer so that the introducer protruded 
l/2 inch past the end of the endotracheal tube. The tube 
was lubricated with lidocaine 2% jelly. To aid endotrach-
eal intubation, pancuronium bromide, 0.126 ug/kg was 
administered by lateral ear vein injection. When the 
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animal was sufficiently paralyzed, laryngoscopy was per-
formed and the vocal cords visualized. The introducer 
with the endotracheal tube in place was then inserted so 
that the introducer could be seen to pass the vocal cords. 
The introducer was then held in place and the endotrach-
eal tube slowly inserted to a predetermined length. The 
endotracheal tube was then connected to the anesthetic 
circuit and the cuff filled until no backflow around the 
tube could be heard. While the animal equilibriated 
(approximately 10 minutes), a femoral cut down was per-
formed as previously described. Blood gases, blood 
pressure, heart rate, and body temperature were monitored 
and recorded. Ventilator rate and/or tidal volume was 
adjusted if necessary to maintain PC0 2 at 35-40 torr. 
When all recorded paramters were determined to be normal 
the experimental procedure was begun. If for any reason 
"normal physiological function" was not established, the 
animal was eliminated and a repeat experiment performed. 
Drug Scheduling 
Three anesthetic agents were studied: ketamine, 
halothane and nitrous oxide. These three agents have 
different clinical uses within the field of anesthesia. 
Each anesthetic was chosen for its dissimilarities from 
the other two so that, hopefully, different actions on 
central adrenergic neuronal transmitters could be demon-
strated. 
Ketamine: 
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Ketamine, a short acting 11 dissociative 11 anesthetic, 
is characterized by both analgesia and narcosis. It was 
used at a dose of 40mg/kg which corresponds well with the 
reported ketamine doses for rabbits in the literature 
(Sung et al., 1973; Biggio et al., 1974). The ketamine 
dose used in humans is 2.0 - 8.0 mg/kg. Interestingly, a 
scan of the literature indicates that the lower an animal 
is on the evolutionary scale, the larger the ketamine 
dose needed for anesthesia. It appears that the dose 
needed for ketamine anesthesia is inversely related to 
phylogeny (Doubrava and Larson, 1971 ). 
In this study, ketamine was given to 20 rabbits 
all weighing between 2.5 and 3.5 kg by lateral ear injec-
tion. Preliminary studies showed that cardiovascular 
depression occurred if ketamine was injected at a concen-
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tration of 100 mglml. The injection concentration 
decided upon for experimentation was 50 mglml. The 
ketamine infusion rate \'las held constant at 1.0 mllmin. 
At this concentration and infusion rate, no respiratory 
or cardiovascular depression was noted. A control sub-
group was administered saline in place of ketamine. 
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All ketamine experiments were begun between 9:00 
and 10:00 a.m. Four animals, one for each of the four 
time points (40, 55, 90, and 105 min.) were handled 
simultaneously. Each animal was prepared with an intra-
ventricular injection site as previously described, 
allowed 1.5 hours recovery, then injected with the 14 c-L-
tyrosine using the schedule shown below. 
D c B A K k i 1 1 
I I I I I I I I 
0 15 30 45 60 75 90 105 
~;li nutes 
Where: 
A i s the 14 c-tyrosine injection time point for 40 min. 
B is the 14c-tyrosine injection time point for 55 min. 
c is the 14 c-tyrosine injection time point for 90 min. 
D i s the 14c-tyrosine injection time point for 105 min. 
K is the ketamine injection time point. 
The thirty minute time period was used for keta-
mine because this is the normal anesthetic time expected 
,, 
:; 
II 
93 
for this agent at this dose. Each animal was monitored 
for body temperature and heart rate. Blood gases were 
drawn as previously described (cf. appendix A for monitor-
ing values). Animals were sacrificed by decapitation. 
Tissue dissection, extraction, fluorometric and isotopic 
procedures were carried out as discussed in the previous 
sections. Catecholamine data obtained from the sham 
injected control animals was not found to differ from the 
awake control group. 
Ketamine Turnover: 
In this study ketamine anesthesia was produced 
using the single intravenous injection technique. To 
measure ketamine turnover using this technique, it is 
necessary to correct the isotopic data such that it 
reflects ketamine's action over the entire turnover time 
course, 0 - 105 minutes, rather than the actual 30 minute 
ketamine anesthesia time. To accomplish this correction 
the formula shown below was applied to each of the 
ketamine data points. The correction was achieved by 
applying the formula: (control DPM - ketamine DPM) 
ketamine fractional time 
where the ketamine fractional time for the 40 minute 
point equals 0.75; for the 55 minute point, 0.545; for 
the 90 minute point, 0.33; and for the 105 minute point, 
0.285. The fractional times were derived by dividing the 
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30 minute ketamine anesthesia time by the total time for 
h · d 30 min. eac per1o , e.g., 
40 min. 
= 0.75 for the 40 minute time 
period. Using this corrected isotopic data, ketamine 
turnover was calculated according to the formula shown in 
the section Turnover Calculations. 
Halothane: 
Halothane is one of the most widely ·used inhala-
tion anesthetics today. It is a halogenated, volatile 
liquid at room temperature and requires a vaporizer for 
controlled use. Halothane produces profound narcosis 
but unlike ketamine results in little, ifa-~nalgesia 
at clinical concentrations. Some degree of muscle relaxa-
tion is common. 
All animals were prepared as previously described. 
Each was intubated and ventilated. Two animals were 
handled simultaneously. Halothane was added into the 
anesthetic circuit using a Foregger Fluomatic vaporizer. 
Two percent halothane was used continuously. When the 
depth of anesthesia was established, femoral, arterial 
and venous catheters were implanted. The animals were 
allowed to stabilize. Blood gases were determined and 
modifications of the respiratory rate or tidal volume 
were made if needed according to PC0 2 values. Each animal 
was maintained on 2% halothane for a 3 hour period. The 
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isotopic injection was adjusted so that each isotope time 
period ended simultaneously with the anesthesia period as 
sho\'tn below. 
Start 
Halothane 
0 
Where: 
A is the 
B is the 
c is the 
0 is the 
60 
14c-tyrosine 
14c-tyrosine 
14c-tyrosine 
14c t . 
- yros1ne 
0 c B A kill 
120 180 
t~inutes 
injection time point for 40 min. 
injection time point for 55 min. 
injection time point for 90 min. 
injection time point for 105 min. 
Blood halothane levels were determined to insure 
a consistent blood halothane on each animal and between 
animals. This level was 12.3 mg% ± 0.85. It should be 
noted that the halothane vaporizer used was rated for a 
minimum flow of 4 liters/minute. This flow rate is 
geared to human use. The considerable excess of gas 
necessarily input into the system was vented through 
an exhausted pressure sensitive pop-off valve. 
A halothane recovery study was also performed. 
Sixteen animals were used. Each group was treated with 
2% halot~ne in precisely the same manner as described 
. ·~ 
before except these animals were allowed to recover for a 
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two hour period (cf. below). 
H HR D c B A k i 11 
13hb' I hb6rs 
I I I I I I I I 
I 3 h Grs 2 10 15 30 45 60 75 90 1 0 5 
~·1inutes 
VJhere: 
A is the 14c-tyrosine injection time point for 40 min. 
B is the 14c . -tyros1ne injection time point for 55 min. 
c is the 14 C-tyrosine injection time point for 90 min. 
D i s the 14 C-tyrosine injection time point for 105 min. 
H is the 3 hour halothane period. 
HR is the 2 hour halothane recovery period. 
During the two hour period, the animals were maintained 
in a 100% oxygen environment. Although continuous blood 
pressure monitoring was impossible due to animal movement, 
blood pressure measurements and blood gas determinations 
were intermittently made throughout the recovery period 
to insure 11 normal physiologic parameters. 11 Blood samples 
were taken prior to sacrifice to determine the blood 
halothane level two hours post anesthesia. Turnover cal-
culation for both the halothane and the halothane recovery 
data was done as shown in the Turnover Calculation section. 
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Nitrous Oxide Studies: 
Nitrous oxide (N 2o), a gas at standard temperature 
and pressure, is supplied in a compressed gas cylinder 
and was connected to the anesthesia flow valve assembly 
by appropriate plumbing. This gas is clinically used to 
produce profound analgesia. In addition, its use in 
balanced anesthesia decreases the concentration of halo-
genated anesthetic needed. Deep narcosis or muscle 
relaxation is not seen at concentrations below 80%. 
For these studies, a 2 liter flow of nitrous 
oxide mixed with a 3 liter oxygen flow was used. In 
this way, a 40% nitrous oxide concentration was delivered 
into the anesthesia circuit. 
Animals were prepared as previously described. 
With the aid of pancuronium bromide, intubation was 
performed and the animals equilibrated on the 40% nitrous 
oxide and 02 gas mixture. The femoral cut down was per-
formed and venous and arterial lines implanted. Gas 
samples were drawn after a 10 minute equilibration period 
and ventilatory parameters were adjusted if needed. Any 
animals which did not demonstrate "normal physiological 
function" were eliminated and repeat experiments performed. 
The intraventricular injection site was prepared 
as described earlier. Physiologic parameters were moni-
tore~( the predetermined intervals. 14c-tyrosine 
I 
98 
injections were made at 40, 55, 90 and 105 minutes prior 
to the 3 hours nitrous oxide termination point. The time 
sequence is shown below. 
Start 
NlO I I D ; B A I K;ll 
~o------~------~6~0------~----~1~2~0------~------~180 
r~ i nut e s 
Where: 
A is the 14c-tyrosine injection time point for 40 minutes. 
B is the 14c-tyrosine injection time point for 55 minutes. 
c is the 14c t . - yros1ne injection time point far 90 minutes. 
D is the 14,. t . .... - yros1ne injection time point far 105 minutes. 
Two animals were ventilated simultaneously on the 
anesthesia circuit. It was found necessary to run two 
animals each day on two consecutive days. The remaining 
processing was handled simultaneously. All phases of the 
nitrous oxide experimentation were identical to that 
described for halothane except for the drug delivered. 
Once sacrificed, all animal tissues and data calculations 
were treated as previously described. 
Halothane and Nitrous Oxide: 
In this study halothane and nitrous oxide were 
used in combination. This halothane-nitrous oxide combi-
nation is widely used as a basal anesthesia resulting in 
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excellent narcosis and muscle relaxation and profound 
analgesia. 
Animals were handled as before. Induction and 
intubation were facilitated with the use of pancuronium 
bromide. Animals were ventilated on halothane (2%) and 
nitrous oxide (40%) in combination. Femoral arterial 
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and venous lines were implanted and the animals allowed 
to equilibrate. Blood gases were monitored and ventila-
tory parameters adjusted if necessary. The three hour 
drug and turnover schedule used was a previously described 
in both halothane and nitrous oxide sections. 
CHAPTER III 
RESULTS 
Introduction: 
This study investigated the effects of ketamine, 
halothane, nitrous oxide and halothane-nitrous oxide in 
combination on dopamine and norepinephrine turnover and 
their endogenous levels to determine if these anesthetic 
agents have common and/or unique effects specific to any 
or all of the brain regions studied. The four brain 
areas considered were the mesencephalon, thalamus, 
hypothalamus and cortex. 
Dopamine and norepinephrine turnover and related 
values are shown in tabular form for the awake (unanes-
thetized) control and experimental groups in tables 5, 
6, 8, 9, 11, 12, 14 and 15. These values include: 
(a) the endogenous content in ug/g, (b) the rate 
constant, which is the rate of isotopic amine disappear-
ance as described by the first derivative of the 
natural log function, (c) the turnover time, which is 
the mean length of time necessary for one molecule to 
turnover and is calculated as the reciprocal of the 
rate constant, and (d) the turnover value itself, which 
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expresses the amount of amine in nanograms which is 
degraded per hour. Awake (unanesthetized) control 
endogenous and turnover levels for norepinephrine and 
dopamine determined in this study are consistent with 
published endogenous and turnover values (Glisson et 
al., 1972; Brodie et al ., 1966; Costa and Neff, 1970). 
Two comparisons are important in this study. 
First, values for each anesthetic agent have been 
compared to values obtained from awake unanesthetized 
animals to determine alterations from normal amine 
metabolism as a result of the anesthetic agent. Second, 
the effects of each anesthetic agent were compared with 
these and the other anesthetic agents to determine like-
ness and dissimilarities between them. 
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Mesencephalon 
Turnover and Endogenous Level as 
Compared to Awake Control: 
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The mean endogenous dopamine level in the 
mesencephalon (table #5) for the awake control was found 
to be 0.333 ug/gram of tissue. Ketamine and nitrous 
oxide administration each resulted in a drop in dopamine 
from control levels. With ketamine a 55% decrease 
{p<O.Ol) in endogenous dopamine occurred, while nitrous 
oxide had only a slight reducing effect (2%) (cf. table 
#5 and figure #4). Halothane and halothane in combina-
tion with nitrous oxide resulted in a significant 
increase in endogenous dopamine compared to awake 
control. The halothane group induced a 51% increase 
{p<0.05) in DA levels and halothane plus nitrous oxide 
in combination resulted in a 203% increase in endogenous 
dopamine {p<O.Ol) (figure #4). 
The endogenous norepinephrine awake control 
level in mesencephalon was found to be 0.323 ug/gram 
(table #6). As in the case of dopamine, a decrease in 
endogenous norepinephrine content occurred with ketamine 
and nitrous oxide. Ketamine resulted in a 56% decrease 
(p<.Ol) and nitrous oxide caused an 11% decrease in 
norepinephrine (figure #4). Halothane alone and in 
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AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
D 0 P A M I N E 
M E S E N C E P .H A L 0 N 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT . TIME ng/g/hr 
0.333±,15 1.190 0.840 396 
0.151±,05 0.747 1.339 248 
0.503±,08 1.520 0.657 506 
0.326±,04 1.LHO 0.709 470 
1.010±,13 1.440 0.627 1450 . 
T A B L E #· 5 
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Table #5 Effects of ketamine (40 mg/kg) halothane (2%), 
nitrous oxide (40% in oxygen), and the combination of 
halothane (2%) plus nitrous oxide (40%) on mesencephalic 
dopamine. Endogenous content is expressed as the mean ~ 
the standard deviation, the rate constant is the rate of 
disappearance of isotopic dopamine over time (also called 
the run off slope), turnover time is shown in fractions 
of hours, and turnover rate is expressed in nanograms per 
gram of brain (wet weight) per hour. The number of 
animals in the control group was 52; in each experimental 
group 16 animals were used. 
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ENDOGENOUS LEVELS AS PERCENT OF AWAKE CONTROL 
Figure #4 
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P<O.OI 
1!1 
iljll. !;,: 
i! 
.,, 
:1, ~ : 
;1:'1 
1,, 
•• 1
1
'.1 
I 
iii 
Iii 
106 
Figure #4 Endogenous dopamine and norepinephrine effects 
in the mesencephalon graphed as a percent of awake control. 
Plots are shown for ketamine (40mg/kg), halothane (2%), 
nitrous oxide (40% in oxygen), and the combination~of 
halothane (2%) plus nitrous oxide (40%). Statistical 
testing was accomplished by Student•s T test and signifi-
cance indicated in terms of probability (p). 
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. A\"/AKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS .OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
N 0 R E P I N E P H R I N E 
ME SEN c·E PH A L 0 N. 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0.323±,08 0.929 1.076 300 
0.143±,06 0.625 1.625 202 
0 .467± .04 1.074 0.931 347 
0.289± .04 0.730 1.370 236 
0 .370± .06 0.806 1.240 260 
TABLE #6 
---
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Table #6 Norepinephrine effects by ketamine (40 mg/kg), 
halothane (2%), nitrous oxide (40% in oxygen), and the 
combination of halothane (2%) plus nitrous oxide (40%) 
in the mesencephalon. Endogenous content is expressed 
as the mean ± the standard deviation, the rate constant 
is the rate of disappearance of isotopic norepinephrine 
over time (ie. run off slope), turnover time is shown in 
fractions of hours, while turnover rate is expressed in 
nanograms per gram of brain (wet weight) per hour. 
The number of animals in ~he control group was 52; in 
each experimental group 16 animals were used. 
'I 
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combination with nitrous oxide resulted in a 45% (p<O.Ol) 
and 28% increase, respectively, in endogenous norepine-
phrine levels over control (figure #4). 
Control dopamine turnover in the mesencephalon 
(table #5) was found to be 396 ng/g/hr. Ketamine 
reduced dopamine turnover significantly 37% (p<O.Ol ). 
Halothane, nitrous oxide, and halothane-nitrous oxide 
in combination increased dopamine turnover. For either 
agent alone the effects were not as dramatic as when 
combined. Halothane alone resulted in a 28% increase 
and nitrous oxide alone resulted in a 19% increase in 
turnover. When used in combination the resulting 
increase was a significant (p<O.Ol) 266% increase (cf. 
table #5 and figure #5). 
Norepinephrine turnover in the mesencephalon 
differed in pattern from that of dopamine. Halothane 
was the only agent that caused an increase in norepine-
phrine turnover (15%). Ketamine, nitrous oxide, 
halothane-nitrous oxide in combination all resulted in 
a decrease in norepinephrine turnover. Nitrous oxide 
resulted in a 21% decrease, halothane in combination 
with nitrous oxide resulted in a 13% decrease in turn-
over and ketamine caused a 33% decrease which was sig-
nificant, p<O.Ol (cf. figure #5). 
100% 
** 366% 
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TURNOVER AS PERCENT OF AWAKE CONTROL 
Figure #5 
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Figure #5 Anesthetic effects on mesencephalic dopamine 
and norepinephrine graphed as a percent of awake control. 
Data is shown for ketamine (40 mg/kg), halothane (2%), 
nitrous oxide (40% in oxygen) and the combination of 
halothane (2%) plus nitrous oxide (40%). Statistical 
comparisons to awake control were made by covariance 
analysis and are reported in terms of probability (p). 
Summary of mesencephalic data: 
1) Ketamine caused significant decreases in 
endogenous dopamine and norepinephrine 
content and turnover. 
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2) Halothane produced in a significant increase 
in endogenous dopamine and norepinephrine 
levels. 
3) The combination of halothane plus nitrous 
oxide resulted in a significant increase in 
endogenous and turnover levels. 
Comparison of Turnover and Endogenous 
Levels Between Anesthetics: 
The second important goal encompassed by this 
dissertation is to compare the NE and DA data of each 
anesthetic agent to the data of all other anesthetic 
agents. This comparison will indicate the similarities 
and dissimilarities in change of amine metabolism 
between individual anesthetics. 
When ketamine, halothane, nitrous oxide, and 
halothane plus nitrous oxide groups were compared to one 
another, all norepinephrine endogenous and turnover 
level comparisons were significantly different with one 
exception. Halothane vs. halothane plus nitrous oxide 
endogenous levels when tested were not significantly 
i 
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different (table #7). In the case of dopamine for these 
same group comparisons, all endogenous levels were 
significantly different, however, only ketamine vs. 
halothane, nitrous oxide, and halothane plus nitrous 
oxide in combination resulted in significant differences 
for the dopamine turnover data (table #7). 
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ANESTHETIC GROUP 
KET VS HAL 
KET vs N20 
KET vs HAL + N20 
HAL vs N2o 
HAL vs HAL + N20 
N2o vs IIAL + N20 
KET = Ketamine 
-~-------,--=-=-::- :-~-
M E S E N C E P H A L 0 N 
DOPAMINE NOREPINEPHRINE 
Endogenous Turnover Endogenous Turnover 
P<0.01 P<0.01 P<0.01 P<0.01 
p <0. 01 P<0.01 p <0. 01 P<0.01 
p <0. 01 p <0. 01 p <0. 01 P<0.01 
p <0. 01 NS p <0. 01 P<O.Ol 
p <0. 01 NS NS P<O.Ol 
p <0. 01 NS p <0. 01 p <0. 01 
I 
-----
HAL = Halothane N20 = Nitrous Oxide 
TABLE #7 
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Table #7 Statistical cross comparisons of endogenous 
levels (Student's T test used) and turnover rates 
(covariance analysis was used) for dopamine and norepine-
phrine in the mesencephalon. Significance is indicated 
in terms of probability (p); insignificant cross compari-
sons are indicated by NS. Cross comparisons for the 
anesthetic groups ketamine (40mg/kg), halothane (2%), 
nitrous oxide (40%), and the halothane-nitrous oxide 
combination are shown. 
Thalamus 
Turnover and Endogenous Levels as 
Compared to Awake Control: 
Control dopamine turnover in the thalamus was 
found to be 422 ng/g/hr (table #8). Ketamine and 
nitrous oxide cause dopamine turnover to slow to 361 
ng/g/hr and 388 ng/g/hr, respectively. This 14% and 
8% drop in dopamine turnover was not significant 
(figure #6). Halothane alone resulted in an increase 
in dopamine turnover to 517 ng/g/hr (23%; p<O.Ol). 
When halothane-nitrous oxide combination was used, no 
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significant effects were found, seemingly a cancellation 
of halothane's increase with nitrous oxide's decrease. 
Noradrenergic turnover was affected to a greater 
extent than was the dopamine turnover. Control nore-
pinephrine turnover was found to be 146 ng/g/hr (table 
#9). Ketamine had the least effect on thalamic turnover. 
Turnover accelerated from 146 ng/g/hr to 156 ng/g/hr 
or 7% (figure #6). Both halothane and nitrous oxide 
caused large increases in norepinephrine turnover in 
this brain area. Nitrous oxide resulted in a 28% 
increase, while halothane caused a 154% rise in turnover 
(i.e., 146 ng/g/hr to 371 ng/g/hr; table #9). When 
these agents were used in combination, proportionately 
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AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
D 0 P A M I N E 
T H A L.A MUS 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0.380±,16 1.110 0.900 422 
0.238±.04 0.951 1.051 361 
0.364± .06 1.360 0.735 517 
0.286±,04 1.020 0.980 388 
1.092±,13 1.180 0.847 448 
- -
TABLE # 8 
_,/ 
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Table #8 Effects of ketamine (40 mg/kg), halothane 
(2%), nitrous oxide (40%) and the combination of 
halothane-nitrous oxide on thalamic dopamine. Endogenous 
content is expressed as the mean ± the standard deviation, 
the rate constant is the rate of disappearance of 
14c-dopamine over time (i.e., run off slope), turnover 
time is shown in fractions of hours and turnover rate is 
expressed in nanograms per gram of brain (wet weight) per 
hour. The number of animals in the control group was 52; 
in each experimental group 16 animals were used. 
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Figure #6 
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I;:;:! I KETAMINE 
~ HALOTHANE 
~ NITROUS OXIDE 
111111 HALOTHANE + 
NITROUS OXIDE 
* 
P<0.05 
** 
P<O.OI 
Figure #6 Anesthetic effects on thalamic dopamine and 
norepinephrine turnover graphed as a percent of awake 
control. Data is shown for ketamine (40 mg/kg), halo-
thane (2%), nitrous oxide (40% in oxygen}, and the 
combination of halothane (2%) plus nitrous oxide (40%). 
Statistical comparisons to awake control were made by 
covariance analysis and are indicated in terms of 
probability (p). 
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AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
N 0 R E P I N E P H R I N E 
T H A L·A MUS 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0.377±.14 0.386 2.591 146 
0.185±.05 0.413 2.421 156 
0.463±.04 0.983 1.017 371 
0.308±.04 0.497 2.012 187 
0 .370± .07 2.020 0.495 761 
TABLE #9 
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Table #9 Norepinephrine effects by ketamine (40 mg/kg), 
halothane (2%), nitrous oxide (40%) and the combination of 
halothane- nitrous oxide in the thalamus. Endogenous 
content is expressed as the mean ± the standard deviation, 
the rate constant is the rate of disappearance of 14c-
norepinephrine over time (ie. run off slope), turnover 
time is shown in fractions of hours, while turnover rate 
is expressed in nanograms per gram of brain (wet weight) 
per hour. The number of animals in the control group· 
was 52; in each experimental group 16 animals were used. 
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a larger than additive increase in norepinephrine turn-
over resulted. The resultant increase was to 761 ng/g/ 
hr or a highly significant 421% increase over control 
(figure #6). 
For the awake control, thalamic endogenous 
dopamine was found to be 0.380 ug/gram of tissue (table 
#8). Administration of ketamine caused endogenous 
dopamine levels to decrease from 0.380 to 0.238 ug/gram 
or 37% (table #8 and figure #7). This did not prove to 
be significant. Halothane and nitrous oxide separately 
also had no significant effect on dopamine endogenous 
levels. However, when in combination, halothane and 
nitrous oxide resulted in a dramatic rise in endogenous 
dopamine. The level rose from 0.380 ug/g control to 
1.092 ug/g, a 187% increase (cf. table #8 and figure #7). 
This finding is strikingly similar to that found in the 
mesencephalon. 
Endogenous norepinephrine levels in the thalamus 
were found to be 0.377 ug/g. Halothane anesthesia 
resulted in a 22% rise in norepinephrine (table #9, 
figure #7). Nitrous oxide, on the other hand, caused 
an 18% fall in the amine content. These two anesthetic 
agents, when combined, seemed to be additive resulting 
in a net cancellation of the individual effects. The 
endogenous norepinephrine level with the halothane and 
** 287% 
DOPAMINE NOREPINEPHRINE 
THALAMUS 
1:::::1 KETAMINE 
E::a HALOTHANE 
~ NITROUS OXIDE 
111111 HALOTHANE + 
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ENDOGENOUS LEVELS AS PERCENT OF AWAKE CONTROL 
Figure #7 
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Figure #7 Effects on endogenous dopamine and norepine-
phrine in the thalamus graphed as a percent of awake 
control. Plots are shown for ketamine (40 mg/kg), hal-
othane (2%), nitrous oxide (40%) and the combination of 
halothane (2%) plus nitrous oxide (40%). Statistical 
testing was accomplished by Student•s T test and signi-
ficance indicated in terms of probability (p). 
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nitrous oxide combination was 0.370 ug/g which was a 2% 
change from control (cf. table #9 and figure #7). In 
the case of ketamine, a 51% (p<O.Ol) decrease in nore-
pinephrine from control occurred. 
Summary of thalamic data: 
1) Halothane increased norepinephrine and 
dopamine turnover. 
2) Halothane plus nitrous oxide increased nore-
pinephrine turnover and increased dopamine 
endogenous levels. 
3) Ketamine decreased endogenous norepinrphrine 
levels. 
Comparison of Turnover and Endogenous 
Levels Between Anesthetics: 
When the groups ketamine, halothane, nitrous 
oxide, and halothane-nitrous oxide were compared to one 
another to examine their likeness and dissimilarities it 
was found that all comparisons were significantly dif-
ferent in the case of both dopamine and norepinephrine 
endogenous data. Only two group comparisons, ketamine 
vs. halothane and halothane vs. nitrous oxide, were 
found to be significantly different for the dopamine 
turnover. For norepinephrine turnover, all groups were 
again significant except for ketamine vs. nitrous oxide 
I 
'I 
~ 
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(table #10). 
l 
co 
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ANESTHETIC GROUP 
KET vs HAL 
KET vs N20 
KET vs HAL + N20 
HAL vs N2o 
HAL vs HAL + N20 
N20 vs HAL + N20 
KET = Ketamine 
THALAMUS 
DOPAMINE NOREPINEPHRINE 
Endogenous Turnover Endogenous Turnover 
-
p <0. 01 p <0. 01 p <0. 01 p <0. 01 
p <0. 0 5 NS p <0. 01 NS 
p <0. 01 NS p <0. 01 p <0. 01 
p <0. 0 5 p <0. 05 p <0. 01 p <O. 01 
p <0. 01 NS p <0. 01 p <0. 01 
p <0. 01 NS p <0. 0 5 p <0. 01 
I 
-
HAL = Halothane N20 = Nitrous Oxide 
T A B L E # 10 
129 
Table #10 Statistical cross comparisons of endogenous 
levels (Student's T test was used) and turnover rates 
(covariance analysis was used) for dopamine and norepine-
phrine in the thalamus. Significance is indicated in 
terms of probability (p); insignificant cross comparisons 
are indicated by NS. Cross comparisons for the anes-
thetic groups ketamine (40 mg/kg), halothane (2%), nitrous 
oxide (40%) and halothane-nitrous oxide are shown. 
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Hypothalamus 
Turnover and Endogenous Levels as 
Compared to Awake Control: 
In the hypothalamus the majority of the changes 
seen in catecholamine metabolism as a result of the 
anesthetic agents tested were found to be dopaminergic. 
Control dopamine turnover in the hypothalamus, shown in 
table #11, was 535 ng/g/hr. Ketamine, halothane, 
nitrous oxide, and halothane-nitrous oxide in combina-
tion resulted in a significant increase over the control 
level. Ketamine and nitrous oxide raised hypothalamic 
dopamine turnover 39% and 32% {p<O.Ol) respectively (cf. 
figure #8). Halothane and halothane-nitrous oxide 
resulted in larger increases in dopamine turnover, 89% 
(p<O.Ol) for halothane alone and 162% {p<O.Ol) for 
halothane in combination with nitrous oxide (cf. figu~e 
#8). 
Relative to dopamine, norepinephrine turnover 
(shown in table #12) was essentially unaffected in the 
hypothalamus by each of the anesthetic agents. Awake 
control norepinephrine turnover was found to be 889 ng/ 
g/hr. Ketamine anesthesia resulted in a 30% drop in 
norepinephrine turnover while halothane and nitrous 
oxide caused a 32% and 31% decrease respectively when 
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AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
D 0 P A M I N E 
H Y P 0 T H A L A M U S 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0.601±.19 0.890 1.124 535 
0.309±.06 1.236 0.809 743 
1.154± .19 1.648 0.607 1012 
0.828±.13 1.175 0.851 706 
2.070±,22J 2.330 0.429 1400 
------- -----· --- -------- -- ------
T A B L E # 11 
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Table #11 Effects of ketamine (40 mg/kg), halothane (2%), 
nitrous oxide (40%) and the combination of halothane-
nitrous oxide on hypothalamic dopamine. Endogenous 
content is expressed as the mean ± the standard deviation, 
the rate constant is the rate of disappearance of 14c-
dopamine over time (i.e., run off slope), turnover rate 
is expressed in nanograms per gram of brain (wet weight) 
per hour. The number of animals in the control group was 
52; in each experimental group 16 animals were used. 
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Figure #8 Hypothalamic effects on dopamine and norepin-
ephrine turnover expressed as a percent of awake control. 
Data is shown for ketamine (40 mg/kg}, halothane (2%), 
nitrous oxide (40%) and the combination o~halothane (2%) 
plus nitrous oxide (40%). Statistical comparisons to 
awake control were made by covariance analysis and are 
indicated in terms of probability (p}. 
~. 
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M 
.-I 
AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
I 
N 0 R E P I N E P H R I N E 
HY POTH A LAM US 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0 .823± .20 1.080 0.926 889 
0.293±,02 0.751 1.332 618 
0.910±,08 0.735 1.361 605 
0.661±,06 0.745 1.342 613 
0.742±,10 1.030 0.971 848 
L- ----·-- --- -- -- - --- - ----
T A B L .E # 12 
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Table #12 Effects on norepinephrine by ketamine (40 mg/ 
kg), halothane (2%), nitrous oxide (40%) and the combina-
tion of halothane (2%) plus nitrous oxide (40%) in the 
hypothalamus. Endogenous content is expressed as the mean 
± the standard deviation, the rate constant is the rate of 
disappearance of the 14c-norapinephrine over time (ie. the 
run off slope), turnover time is shown in fractions of 
hours, and turnover rate is expressed in nanograms per 
gram of brain (wet weight) per hour. The number of ani-
mals in the control group was 52; in each experimental 
group 16 animals were used. 
compared to awake control. Halothane when used in 
conjunction with nitrous oxide had little effect. A 
5% drop in NE turnover was seen (cf. figure #8). 
The mean control endogenous dopamine level in 
the hypothalamus was found to be 0.601 ug/g of tissue 
(table #11). Ketamine, the only treatment group to 
lower endogenous dopamine levels, resulted in a mean 
value of 0.309 ug/g or a 49% decrease (figure #9). 
Halothane and nitrous oxide alone and in combination 
resulted in dramatic increases in endogenous dopamine 
levels. A 92% {p<0.05) increase (0.601 ug/g to 1.154 
ug/g; table #11) occurred with halothane anesthesia 
(figure #9). Nitrous oxide increased dopamine levels 
38% over control. This effect is seen in other brain 
areas. Nitrous oxide in combination with halothane 
significantly increased endogenous dopamine levels to 
2.07 ug/g (table #11) or a 245% increase over control 
(cf. figure #9). 
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Norepinephrine endogenous levels in the hypo-
thalamus were generally unaffected by the anesthetic 
agents tested. Ketamine, the only anesthetic to have 
significant effect upon endogenous norepinephrine levels 
resulted in a 64% drop from control (0.823 ug/g to 0.293 
ug/g; cf. table #12 and figure #9). In the case of 
halothane a nonsignificant 11% increase in endogenous 
* 
** 345% 
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Figure #9 
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Figure #9 Effects on endogenous dopamine and norepine-
phrine in the hypothalamus graphed as a percent of awake 
control. Plots are shown for ketamine (40 mg/kg), hal-
othane (2%), nitrous oxide (40%) and the combination 
halothane - nitrous oxide. Statistical testing was 
accomplished by Student•s T test and significance indicat-
ed in terms of probability (p). 
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norepinephrine levels resulted (see table #12 and figure 
#9) while with nitrous oxide a 20% decrease was found. 
When the two agents were used in combination the effect 
resultant was a nonsignificant 10% drop in endogenous 
norepinephrine levels. 
Summary of hypothalamic data: 
1) Ketamine resulted in a significant decrease 
in both dopamine and norepinephrine endogen-
ouse levels. Dopamine turnover was signifi-
cantly increased. 
2) Halothane significantly increased both 
turnover and endogenous dopamine levels. 
3) Nitrous oxide increased dopamine turnover 
and endogenous levels. 
4) The combination of halothane-nitrous oxide 
resulted in increased turnover and endogenous 
dopamine levels. 
Comparison of Turnover and Endogenous 
Levels Between Anesthetics: 
When the groups ketamine, halothane, nitrous 
oxide, and halothane-nitrous oxide were compared to one 
another to examine their likenesses and dissimilarities, 
it was found that for both dopamine and norepinephrine 
all endogenous level comparisons were found to be 
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significantly different from one another except for 
nitrous oxide vs. halothane-nitrous oxide, norepinephrine 
only. For dopamine turnover all comparisons were signi-
ficant except for ketamine vs. nitrous oxide. For 
norepinephrine turnover distinct alterations of meta-
bolism appeared only for the halothane-nitrous oxide 
group when compared to either halothane or nitrous 
oxide (cf. table #13). 
N 
o::;t 
....... 
ANESTHETIC GROUP 
KET vs HAL 
KET vs N20 ... 
KET vs HAL + N20 
HAL vs N20 
HAL vs HAL + N20 
N2o vs HAL + N20 
KET = Ketamine 
H Y P 0 T H A L A M U S 
DOPAMINE NOREPINEPHRINE 
Endogenous Turnover Endogenous Turnover 
P<0.01 P<0.01 P<0.01 NS 
P<0.01 NS P<0.01 NS 
P<0.01 P<0.01 P<0.01 NS 
P<0.01 P<0.01 P<0.01 NS 
p <O. 01 P <o. o 1 P<0.01 P<0.05 
p <0. 01 P<0.01 NS P<0.05 
' 
HAL = Halothane N20 = Nitrous Oxide 
T A B L E # 13 
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Table #13 Statistical cross comparison of endogenous 
levels (Student's T test was used) and turnover rates 
(covariance analysis was used) for dopamine and norepine-
phrine in the hypothalamus. Significance is indicated in 
terms of probability (p); insigifnicant cross comparisons 
are indicated by NS. Cross comparisons for the anesthetic 
groups ketamine (40 mg/kg), halothane (2%), nitrous oxide 
(40%) and the combination of halothane (2%) plus nitrous 
oxide (40%) in combination are shown. 
Cortex 
Turnover and Endogenous Levels as 
Compared to Awake Control: 
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Control dopaminergic turnover in the cortex was 
found to be 112 ng/g/hr (table #14). Ketamine, which 
caused a decrease in dopamine turnover in the mesen-
cephalon and thalamus, also caused a decrease in the 
cortex. Dopamine turnover in the ketamine group was 
found to be 72 ng/g/hr, which is a significant 36% 
decrease (cf. table #14 and Figure #10). Halothane 
also decreased dopamine turnover. A dramatic drop from 
112 ng/g/hr was seen. This was a significant 76% drop 
as is shown in figure #10. Nitrous oxide had little 
effect on dopamine turnover, however, in combination 
with halothane, dopamine turnover increased to 258 ng/ 
g/hr, a marked 111% increase over control (cf. figure 
#10 and table #14). 
Dramatic changes were seen in cortical norepine-
phrine turnover by all anesthetics. Awake control 
norepinephrine turnover shown in table #13 was 80 ng/g/ 
hr. Ketamine, halothane, nitrous oxide, and halothane-
nitrous oxide (seen in figure #10) resulted in increased 
turnover levels from awake control. Ketamine caused a 
120% increase to 175 ng/g/hr. Halothane and nitrous 
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AWAKE CONTROL 
KETAMINE. ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
D 0 P A M I N E 
CORTEX 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0.105±,10 1.070 0.935 112 
0.079±.04 0.689 1.451 72 
0 .184± I 03 0.259 3.860 27 
0.133±,02 1.030 . 0.971 108 
0 .362± .04 0.712 1.404 258 
T A B L E # 14 
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Table #14 Effect of ketamine (40 mg/kg), halothane (2%), 
nitrous oxide (40%), and the combination of halothane-
nitrous oxide on cortical dopamine. Endogenous content 
is expressed as the mean ± the standard deviation, the 
rate constant is the rate of disappearance of 14 C-dopamine 
over time (i.e., the run off slope), turnover rate is 
expressed in nanograms per gram of brain (wet weight) per 
hour. The number of animals in the control group was 52; 
in each experimental group 16 animals were used. 
DOPAMINE 
* 
** 400% 
NOREPINEPHRINE 
CORTEX 
TURNOVER AS PERCENT OF CONTROL 
Figure #10 
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r--··1 ::::: KETAMINE 
151 HALOTHANE 
~ NITROUS OXIDE 
111111 HALOTHANE + 
NITROUS OXIDE 
* 
P<0.05 
** 
P<O.OI 
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Figure #10 Cortical effects on dopamine and norepine-
phrine turnover expressed as a percent of awake control. 
Bar graphs are shown for ketamine (40 mg/kg), halothane 
(2%), nitrous oxide (40%) and the combination halothane-
nitrous oxide. Statistical comparisons to awake control 
were made by covariance analysis and are indicated in 
terms of probability (p). 
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oxide increased norepinephrine turnover 122% and a 145%, 
respectively (cf. table #15 and figure #10). When 
nitrous oxide and halothane were used in combination, 
turnover increased 300% (p<O.Ol, figure #10). 
For the awake control, cortical endogenous dopa-
mine was found to be 0.105 ug/gram of tissue (table #14). 
Ketamine was the only anesthetic to lower dopamine endo-
genous levels in the cortex, and this was a nonsignifi-
cant 25% decrease (cf. table #14 and figure #11). On 
the other hand, halothane, nitrous oxide and the two 
agents in combination increased cortical dopamine 
endogenous levels, halothane alone increased dopamine 
from 0.105 ug/g control to 0.184 ug/g, a 75% increase 
(p<O.Ol ). Nitrous oxide alone effected a 22% increase 
in dopamine levels. Most significant was the finding 
that nitrous oxide in combination with halothane pro-
duced a dramatic 245% increase in dopamine level 
(figure #11). 
Awake control endogenous norepinephrine levels 
in the cortex were found to be 0.160 ug/gram of tissue. 
As was demonstrated in the other three brain areas, 
ketamine caused a significant decrease in endogenous 
norepinephrine level. As seen in table #15 ketamine 
anesthesia resulted in a significant fall to 0.075 ug/ 
gram of tissue, a 54% drop (figure #11 ). Halothane 
~ 
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AWAKE CONTROL 
KETAMINE ANESTHESIA 
HALOTHANE ANESTHESIA 
NITROUS OXIDE ANESTHESIA 
HALOTHANE PLUS 
NITROUS OXIDE ANESTHESIA 
N 0 R E P I N E P H R I N E 
C 0 R T E X 
ENDOGENOUS RATE TURNOVER TURNOVER 
ug/gram CONSTANT TIME ng/g/hr 
0 .160± .07 0.498 2.001 80 
0.075±,01 1.093 0.915 175 
0.255±,02 1.109 0.902 177 
0.186±,03 1.210 0.826 194 
0.196± 2.002 0.500 320 
T A B L.E # 15 
I 
I 
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Tab1e #15 Effect of ketamine (40 mg/kg), ha1othane (2%), 
nitrous oxide (40%), and the combination of ha1othane-
nitrous oxide on cortica1 dopamine. Endogenous content 
is expressed as the mean ! the standard deviation, the 
rate constant is the rate of disappearance of 14c-dopamine 
over time (i.e., the run off s1ope), turnover rate is 
expressed in nanograms per gram of brain (wet weight) per 
hour. The number of anima1s in the contro1 group was 52; 
in each experimenta1 group 16 anima1s were used. 
100% 
** 
** 345% 
DOPAMINE NOREPINEPHRINE 
CORTEX 
ENDOGENOUS AS PERCENT OF CONTROL 
Figure #11 
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151 HALOTHANE 
~ NITROUS OXIDE 
111111 HALOTHANE + NITROUS OXIDE 
** 
P<O.OI 
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Figure #11 Effects on endogenous dopamine and norepine-
phrine in the cortex graphed as a percent of awake control. 
Plots are shown for ketamine (40 mg/kg), halothane (2%), 
nitrous oxide (40%), and the combination halothane-
nitrous oxide. Statistical testing was accomplished by 
Student's T test and significance indicated in terms of 
probability (p). 
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alone increased endogenous norepinephrine levels a 
significant 59%. Nitrous oxide alone did not signifi-
cantly change endogenous cortical norepinephrine levels. 
The use of nitrous oxide in combination with halothane 
increased the endogenous norepinephrine levels from 0.160 
control, to 0.196 ug/g, a 23% increase. 
Summary of cortical data: 
1) Ketamine decreased dopamine turnover and 
increased norepinephrine turnover. Nore-
pinephrine endogenous levels were increased. 
2) Halothane increased norepinephrine turnover 
and endogenous levels and dopamine endogenous 
levels. Dopamine turnover was decreased. 
3) Nitrous oxide increased only norepinephrine 
endogenous levels. 
4) The combination of halothane-nitrous oxide 
increased dopamine and norepinephrine turn-
over. Dopamine endogenous levels were also 
significantly increased. 
Comparison of Turnover and Endogenous 
Levels Between Anesthetics: 
When ketamine, halothane, nitrous oxide, and 
halothane-nitrous oxide groups were compared to one 
another, all dopamine endogenous and turnover level 
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comparisons were significantly different with the excep-
tion of ketamine vs. halothane-nitrous oxide, turnover 
only (table #16). In the case of dopamine for these 
same group comparison, all endogenous data was signifi-
cantly different except for nitrous oxide vs. halothane-
nitrous oxide. With respect to the norepinephrine com-
parisons, only ketamine, halothane, and nitrous oxide 
vs. halothane-nitrous oxide were found significant. 
Halothane Recovery: 
When turnover and endogenous levels were assayed, 
in animals allowed to recover for two hours post halo-
thane anesthesia, it was found that dopamine turnover 
in the mesencephalon, thalamus, hypothalamus, and cortex 
returned to levels 16%, 17%, 6%~ 2% different from awake 
control, respectively. None of these values demonstrated 
a significant difference from control (cf. figure #12). 
In the case of norepinephrine, mesencephalic 
turnover returned to a level 9% below control, while 
hypothalamic levels returned to a level 5% above control. 
A 45% decrease in turnover was demonstrated for norepine-
phrine turnover in the thalamus, however, this decrease 
was not significant when compared to awake control. The 
cortex showed a 101% increase in norepinephrine turnover 
(p<O.Ol) post anesthesia. This finding is similar to 
that effect seen for all anesthetics studied. 
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ANESTHETIC GROUP 
KET vs HAL 
KET vs N20 
KET vs HAL + N20 
HAL vs N20 
HAL vs HAL + N20 
N20 vs HAL + N20 
KET = Ketamine 
CORTEX 
DOPAMINE NOREPINEPHRINE 
Endogenous Turnover Endogenous Turnover 
-
p <0. 01 P<0.01 P<0.01 NS 
p <0. 01 P<O.Ol P<O. 01 NS 
p <0. 01 NS p <0. 01 P<0.01 I 
p <0. 01 p <0. 01 P<0.01 NS 
p <0. 01 p <0. 01 P<0.01 P<0.01 
p <0. 01 p <0. 01 NS P<0.01 
I 
HAL = Halothane N20 = Nitrous Oxide 
T A B L E # 16 
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Table #16 Statistical cross comparisons of endogenous 
levels (Student's T test was used) and turnover rates 
(covariance analysis was used) for dopamine and nore-
pinephrine in the cortex. Significance is indicated in 
terms of probability (p); insignificant cross comparisons 
are indicated by NS. Cross comparisons for the anesthetic 
groups ketamine (40mg/kg), halothane (2%), nitrous oxide 
(40%), and the combination halothane (2%) plus nitrous 
oxide (40%) are shown. 
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MESENCEPHALON 
E3 THALAMUS 
~ HYPOTHALAMUS 
111111 CORTEX 
** 
P<.OI 
® TWO HOUR POST 
HALOTHANE 
DOPAMINE NOREPINEPHRINE 
HALOTHANE RECOVERY® 
TURNOVER AS PERCENT OF AWAKE CONTROL 
Figure #12 
Figure #12 Effects on dopamine and norepinephrine 
turnover levels in the mesencephalon, thalamus,hypo-
thalamus, and cortex two hours post halothane anes-
thesia graphed as a percent of awake control. 
Statistical comparisons to awake control were made 
by covariance analysis and reported in terms of 
probability {p). Sixteen animals were used for the 
halothane recovery group. 
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With regard to endogenous levels, only the 
mesencephalon and cortex showed significan1 changes in 
dopamine when compared to control levels. The mesen-
cephalon showed a 51% increase (p<0.05) while the cortex 
showed a 93% increase {p<O.Ol). All brain areas studied 
were found to have significant decreases in norepine-
phrine levels post anesthesia. These decreases ranged 
from 63% to 73% of control (cf. figure #13). 
** 
* 
DOPAMINE NOREPINEPHRINE 
HALOTHANE RECOVERY 
Ill MESENCEPHALON 
1§1 THALAMUS 
~ HYPOTHALAMUS 
111111 CORTEX 
* P<.05 
** P<.OI 
ENDOGENOUS LEVELS AS PERCENT OF AWAKE CONTROL 
Figure #13 
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Figure #13 Effects on dopamine and norepinephrine 
endogenous levels in the mesencephalon, thalamus, 
hypothalamus, and cortex two hours post halothane 
anesthesia graphed as a percent of awake control. 
Statistical comparisons were made by Student's T 
test and reported in terms of probability (p). 
Sixteen animals were used for the halothane recovery 
group. 
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CHAPTER IV 
DISCUSSION 
The mechanism by which anesthetic agents produce 
central nervous system anesthesia has been formally 
queried since the late eighteen hundreds when Meyer 
(1899) and Overton (1901) first proposed the lipid theory 
of anesthesia. Adding great impetus to this search over 
the years has been the belief that knowing the central 
mechanism of anesthesia would allow the tailoring of a 
more perfect anesthetic agent. Unfortunately, a careful 
examination of the research findings has left more 
questions unanswered than answered. 
Two basic approaches to the research of anes-
thesia have evolved. The first, micromolecular, is 
limited in scope to the molecular interaction of 
anesthetics within the cell. Theories arising from 
these works have generally tied the primary anesthetic 
effect to a direct action on nerve cell components. 
These theories have been discussed at length in the 
Introduction of this dissertation under the Biophysical 
Anesthetic Mechanism. 
The second approach, macromolecular, considers 
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that anesthetics affect the central synapses. Of 
importance in this concept is how anesthetics affect the 
central transmitter systems. Since comprehensive inves-
tigation into the effect of anesthetic agents on central 
dopaminergic and noradrenergic nerve activity had not 
been carried out, the aim of this study was to investi-
gate anesthetic action in the central adrenergic nervous 
system with particular attention to the following 
questions: 
1) Is the central adrenergic nervous system 
affected by anesthetic agents as determined 
by adrenergic amine turnover? 
2) If affected, are neurons of the same type 
(i.e., dopamine or norepinephrine) affected 
in an identical manner in all brain regions? 
3) Do clinically different anesthetics have 
different effects centrally on adrenergic 
neurotransmitters? 
To answer these questions three clinically 
different anesthetics, ketamine, halothane, and nitrous 
oxide as well as the combination of halothane-nitrous 
oxide were studied to determine their effect on dopa-
mine and norepinephrine turnover in four brain areas. 
The turnover data was used as an index of neuronal 
activity for these two adrenergic transmitter systems 
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(Costa and Neff, 1970). 
With respect to the above three questions the 
results of this study provide the following answers and 
allow several conclusions to be drawn. 
Is the central adrenergic nervous system affected 
by anesthetic agents as determined by adrenergic 
turnover? 
Simply summarized, the turnover results from 
this study show that ketamine anesthesia is associated 
with significant dopamine decreases in the mesencephalon 
and cortex with an increase in the hypothalamus; halo-
thane caused similar dopamine changes in the hypothalamus 
and cortex but differed in that a significant increase in 
thalamic dopamine turnover was found with no change seen in 
the mesencephalon. Nitrous oxide results were markedly 
different than those produced by ketamine and halothane 
in that only one area was affected (i.e., an increase 
in the hypothalamus). Combination halothane plus nitrous 
oxide resulted in significant increases in dopamine 
turnover in the mesencephalon, hypothalamus, and 
cortex or three out of four areas studied. 
For norepinephrine, ketamine was associated 
with an increased turnover in the cortex and a decreased 
turnover in the mesencephalon. Halothane influenced 
norepinephrine turnover similarly in the cortex, did 
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not produce any changes in the mesencephalon, as did keta-
mine, and increased norepinephrine turnover in the thalamus. 
Nitrous oxide affected norepinephrine only in the cortex 
(an increase). The combination of halothane-nitrous oxide 
resulted in significant increases in the thalamus and cortex. 
These data indicate that anesthesia by ketamine, 
halothane, nitrous oxide and the combination of halothane 
and nitrous oxide is associated with altered dopamine and 
norepinephrine turnover when compared to awake control. 
Importantly, these results suggest why conflicting 
findings on whole brain were reported. With ketamine 
anesthesia, Biggio et al. (1974) suggested an increased 
dopamine turnover while Sung et al. (1973) reported a 
decrease. Both research groups used whole brain samples. 
Our ketamine data clearly shows both an increase (hypothala-
mus) and decrease (mesencephalon and cortex) in dopamine 
turnover. With respect to halothane, our data generally 
support findings of Nikki et al. (1971) and refute that 
of Anden et al. (1974) and Ngai et al. (1969a), which 
reported halothane to have no effect on dopamine and nore-
pinephrine turnover in whole brain. Our findings further 
suggest that individual dopamine and norepinephrine trans-
mitter systems operate independently of one another as both 
systems demonstrated distinctly different turnover changes 
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in conjunction with the same anesthetic agent. This is 
demonstrated by the finding that both ketamine and 
halothane resulted in decreased cortical dopaminE 
turnover, while both increased norepinephrine turnover. 
Similar results were obtained by Biggio et al. (1974) 
and Nikki et al. (1971 ). 
Endogenous amine results obtained in this study 
also support involvement of the adrenergic system with 
anesthesia (significant change was observed for all 
anesthetic groups except for nitrous oxide), however, 
such data cannot reflect neuronal activity. It is this 
lack of correlation between endogenous levels and 
neuronal activity that has led researchers to determine 
turnover rather than just the endogenous content of a 
transmitter to predict central neuronal activity (Costa, 
1971). 
the same t e (i.e., 
affected the same in 
Early attempts to ascertain the involvement of 
the central adrenergic system with anesthesia were 
carried out on whole brain samples with little success. 
Both Anden et al. (1974) and Ngai et al. (1969a) found 
no effect by halothane anesthesia on norepinephrine 
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and dopamine. Present results offer a reason for the 
early failures. With all anesthetics studied: ketamine, 
halothane, nitrous oxide, and halothane-nitrous oxide, 
the change in NE and DA turnover in individual brain 
regions was non-uniform. Increased turnover in one brain 
area with decreased turnover in another area, approxi-
mately in proportion, as was the case with halothane 
dopamine turnover, would mask by cancellation anesthetic 
effects on turnover when whole brain samples are used 
as in the earlier studies. 
Importantly, this study has provided evidence 
of non-uniform regional changes in dopamine and norepine-
phrine neuronal activity associated with anesthesia. 
The concept that anesthetics have regionally different 
central actions was previously proposed by Roizen (1976) 
on the basis of endogenous catecholamine data and local 
changes in glucose metabolism (Shapiro et al., 
1978). Likewise, Ngai et al. (1978) proposed regional 
effects for halothane and cyclopropane with respect to 
acetylcholine turnover. Clearly, the evidence supports 
regional effects of anesthetics on neural activity, 
however the effect varies from region to region. The 
meaning of these regional differences relative to anes-
thesia remains at present elusive. 
To postulate that the demonstrated regional 
r 
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turnover changes for dopamine and norepinephrine are 
related, at least temporally to anesthesia, one should 
expect these turnover changes to revert to awake control 
levels post anesthesia. A test of this hypothesis 
demonstrated two hours post halothane anesthesia that 
turnover changes seen during anesthesia do in fact revert 
to values not significantly different from the awake 
control. Only cortical norepinephrine turnover did not 
return to the pre-anesthetic level. Interestingly, 
the only effect common to all agents during anesthesia 
was this increase in cortical norepinephrine turnover. 
The relationship of this effect to the increased 
norepinephrine turnover post anesthesia is unknown. 
Do clinically different anesthetics have different 
effects centrally on adrenergic neurotransmitters? 
The anesthetics used were chosen for their 
differences in clinical effect. There are now many 
classes df anesthetic agents (e.g., dissociative, inha-
lation, narcotic, barbiturate) each with its own clini-
cally unique type of anesthesia. Some agents have good 
hypnotic action, while having little to no analgesic 
activity (e.g., barbiturates), while others produce good 
analgesia at clinical doses (e.g., ,N 20). It is unknown 
whether or not all anesthetics have common effects 
centrally, although common sense might dictate that 
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clinically different anesthetics should result in diff-
erent central effects as well. To test this hypothesis, 
individual ketamine, halothane, nitrous oxide, and 
halothane-nitrous oxide turnover and endogenous amine 
data from the same brain region were cross-correlated. 
By design, a significant difference in turnover activity 
between the two anesthetic agents being compared indi-
cated a different effect of each agent on that amine 
system. And conversely, a lack of significance between 
the effects of different anesthetics was interpreted to 
indicate a similarity in effect on that brain region. 
This type of a comparison is problematic and generally 
limited in scope for the following reasons. It is 
difficult to provide evidence of equal anesthetic depth 
between intravenous and inhalation anesthesia. Nitrous 
oxide at the concentration used is only analgesic, not 
anesthetic. It is also well documented that the addition 
of nitrous oxide to halothane increases halothane's 
potency. Therefore, in this study where the same con-
centration of halothane is used with and without nitrous 
oxide the levels of anesthesia of these two groups must 
be different. 
Even though there are differences in anesthetic 
level these comparisons allow one to determine quali-
tative differences between these clinically different 
anesthetics. This is an important step in determining 
similarities of effect on central neurotransmitter 
systems by anesthetic agents. 
Ketamine vs. Halothane: 
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Ketamine anesthesia has been termed 11 dissociative 11 
and is characterized by possible increases in EEG activi-
ty, profound analgesia, normal muscle tone, and catatonia. 
Halothane is a potent anesthetic marked by poor anal-
gesia, depressed EEG activity, minimal depression of 
neuromuscular junctions, and causes profound narcosis. 
These two agents present themselves as clinically 
different anesthetics. 
When ketamine turnover was compared with that of 
halothane, dopamine turnover levels were significantly 
different in all four brain regions. Norepinephrine 
turnover comparisons were significantly different in two 
areas, the mesencephalon and thalamus, and not different 
(or similar) in the other two areas, hypothalamus and 
cortex. The conclusion derived was that ketamine and 
halothane have dissimilar patterns of effect on regional 
amine metabolism. This conclusion is supported by 
multi unit electrophysiological findings which also show 
regional differences for these two anesthetics (Domino, 
1968; Massopust et al., 1972). 
r 
Ketamine vs. Nitrous Oxide; Ketamine vs. Nitrous 
Oxide-Halothane: 
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Nitrous oxide, when used in clinical concentra-
tions, is a potent analgesic agent with few other 
clinically significant effects. Nitrous oxide is 
therefore similar to ketamine as an analgesic. 
Comparison of dopamine and norepinephrine 
turnover data for ketamine and nitrous oxide demonstra-
ted some similarities for these two agents. Thalamic 
and hypothalamic dopamine changes were similar, while 
norepinephrine turnover was significantly different in 
three out of the four areas studied, the thalamus, 
hypothalamus, and cortex. Further, when ketamine data 
is compared to the halothane-nitrous oxide combination 
there were fewer areas of significant difference compared 
to halothane alone and more areas of difference when 
compared to nitrous oxide alone, which is qualitatively 
what one might expect. It should be noted that this 
comparison is based on the overall number of significant 
findings. 
Halothane vs. Nitrous Oxide: 
When halothane and nitrous oxide were compared 
one might anticipate different effects in central 
adrenergic activity since these are two quite different 
clinical agents. When turnover data was compared some 
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areas showed similarity of effect and some statisti-
cally different effects. The thalamus, hypothalamus, 
and cortex showed significantly different dopamine 
changes, while in the case of norepinephrine, turnover 
comparisons showed different effects in the mesencephalon 
and thalamus. It can be concluded that halothane and 
nitrous oxide each alter regional adrenergic neuronal 
activity in a different fashion. 
Halothane vs. Halothane-Nitrous Oxide; 
Nitrous Oxide vs. Halothane-Nitrous Oxide: 
Comparison of the halothane-nitrous oxide 
combination to halothane alone and nitrous oxide alone 
provided an interesting finding. The overall effect on 
turnover due to halothane-nitrous oxide combination was 
greater than either agent alone or the sum of the indi-
vidual turnover effects. In the mesencephalon and 
thalamus, the magnitude of change indicated a supra-
additive effect, while in cortex a complete reversal in 
the direction of change occurred. These findings are 
novel insofar as central adrenergic neural activity is 
involved, although in the periphery several authors 
have suggested that the combination of halothane plus 
nitrous oxide results in measured effects attributable 
to neither agent alone. Hornbein et al. (1969) and 
Bahlman et al. (1971) measured cardiovascular and 
respiratory parameters, while Smith et al. (1970) 
recorded sympathetic out flow. Both groups found a 
disproportionate increase in response when nitrous 
oxide was added to halothane anesthesia. Fukunaga and 
Epstein (1973) found a large increase in sympathetic 
out flow when nitrous oxide was added to halothane, 
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however, if the same animal had a mid-collicular lesion, 
addition of nitrous oxide was then found to cause a 
decrease in sympathetic activity. These authors postu-
lated a supra-collicular site as responsible for the 
combined effects. 
Although evidence of central and peripheral 
supraadditive anesthetic actions has been demonstrated, 
the mechanism and/or significance of these actions 
remain unknown. 
It can be concluded from this study that the 
clinically different anesthetics ketamine, halothane, 
nitrous oxide, and the combination halothane-nitrous 
oxide do produce individual (supraadditive) effects on 
regional central catecholamine turnover. 
Anesthesia in Relation to Transmitter 
~stems - a Perspective: 
When one considers change in adrenergic turnover 
relative to anesthesia, it is important to consider the 
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direction of the observed change. Conceptually, it would 
seem easier to relate a decrease rather than increase in 
neuronal activity to a state of anesthesia. This stems 
from the long standing, and generally unproven, hypothe-
sis that the CNS is deactivated during anesthesia. This 
concept began to change when Winters et al. (1967) 
reclassified anesthetic agents with respect to EEG 
activity during surgical anesthesia. He found that not 
all agents acted in the classical sense to cause EEG 
depression. Ether, barbiturate, and halothane did act 
in this fashion, while such agents as nitrous oxide, 
gama hydroxybutyrate, phencyclidine, ketamine and 
enflurane all could increase brain EEG activity at 
clinical dose~. 
It has been considerably more difficult to 
obtain a good neurochemical correlate similar to that of 
EEG activity to relate to anesthesia. Recent evidence 
has related cholinergic neuronal activity to both EEG 
activity and anesthesia (Ngai et al., 1978). Anesthet-
ics shown to decrease EEG activity have also been shown 
to decrease acetylcholine turnover, while other anes-
thetics known to increase EEG activity have been shown 
in some cases to increase acetylcholine turnover (Ngai 
et al ., 1978). Moreover, clinical and experimental 
evidence utilizing various cholinergic agonists and 
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antagonists have demonstrated that cholinergic manipula-
tion will affect the anesthetic process (Winter, 1976; 
Horrigan, 1978). Importantly, physostigmine has been 
shown in humans to reduce the recovery time post anes-
thesia (Smith et al., 1976). 
The central cholinergic system probably does not 
act as an independent neurochemical system (Sethy et 
al ., 1976). The complex neuronal circuitry containing 
known and unknown transmitters that appear to work in 
concert have yet to be sufficiently unraveled. Results 
from this study suggest the premise that reported 
increases and decreases in cholinergic activity with 
anesthesia might be the result of induced changes from 
stimulatory or inhibitory neurotransmitter systems. 
Serotonin turnover has been generally shown to 
decrease with anesthesia (Sung et al., 1973; Bourgoin 
et al ., 1975) and gamma-amino butyric acid (GABA), a 
known central inhibitory transmitter, was proposed by 
Cheng and Brunner (1975) to cause post synaptic inhibi-
tion and anesthesia through increased GABA concentra-
tion in the cortex. Other work related to GABA has 
been carried out using gamma-butyrolactone, a precursor 
to GABA, and gamma-hydroxybutyrate (GHB), a metabolite 
of GABA and an anesthetic agent itself. Gessa et al. 
(1966) demonstrated that GHB-induced anesthesia was 
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associated with significant increases in brain dopamine. 
A concomitant decrease in acetylcholine turnover with 
GHB anesthesia was suggested by the data of Sethy et al. 
(1976). Further gamma-butyrolactone was demonstrated to 
increase central dopamine content presumably by increas-
ing tyrosine hydroxylase activity (Murrin and Roth, 
1976). 
Johnston et al. (1975) and Batista et al. (1973) 
have postulated dopamine to be an inhibitory transmitter 
in relation to anesthesia. In general, results from this 
study show that anesthetics outlined by Winters et al. 
(1967) to decrease EEG activity (halothane in this study) 
caused increased dopamine turnover in almost all brain 
areas studied. Conversely a decrease in dopamine turn-
over was seen with anesthetics which caused increased 
EEG activity (ketamine and nitrous oxide in this study). 
This inverse relationship between EEG activity and 
acetylcholine turnover (Ngai et al ., 1978) and dopamine 
turnover (this study) could relate to an inhibitory 
effect of dopamine on the central cholinergic neuro-
transmitter system with resultant anesthesia. Such 
an acetylcholine inhibition by dopamine is known to 
exist in the nigrostriatal system (Cooper et al ., 1974). 
In the same context, nitrous oxide when added to halo-
thane anesthesia is known to increase halothane 1 S 
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potency (as previously discussed). This dopamine based 
theory of anesthesia would predict a potentiation of 
the halothane induced increase in dopamine turnover when 
nitrous oxide is added to halothane. This was demon-
strated in this study. 
Further support of dopamine involvement during 
anesthesia comes from studies by Fyro et al. (1975), who 
have shown in humans that halothane-nitrous oxide anes-
thesia increases homovanillic acid (HVA) output into the 
cerebral spinal fluid strongly suggesting an increase 
in dopamine turnover and therefore dopaminergic nerve 
activity. 
Additional supportive evidence comes from 
studies using anti-dopaminergic compounds such as 
pimozide, which was shown to antagonize certain types 
of anesthesia (Hatch, 1974) while drugs known to ele-
vate dopamine concentration such as L-dopa have been 
shown to increase anesthetic potency (Johnston et al., 
1975). 
Thus accumulating evidence from both animal and 
human studies support the concept of increased neuronal 
activity in a proposed central dopamine inhibitory 
system during anesthesia. The validity of this hypo-
thesis must await future experimental results. 
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SUMMARY 
To summarize the findings of this study, it was 
demonstrated that the anesthetic agents ketamine, halothane, 
nitrous oxide and the combination of halothane - nitrous 
oxide significantly alters dopamine and norepinephrine 
turnover in select brain regions. In brief, ketamine 
results in a significant decrease in both mesencephalic 
and cortical turnover and an increase in hypothalamic 
dopamine turnover. Ketamine decreased cortical norepineph-
rine turnover. HaJothane results were different from those 
found with ketamine. Increased thalamic and hypothalamic 
dopamine was found with a concomitant decrease in cortical 
dopamine turnover. Halothane increased both thalamic and 
cortical norepinephrine turnover. Two hours post halothane 
anesthesia, turnover rates in all brain areas affected were 
found to have returned to control except for cortical nore-
pinephrine. Nitrous oxide had only two effects on catechol-
amine turnover. An increase in hypothalamic dopamine and an 
increase in cortical norepinephrine were found. Of interest 
were the large changes in turnover found when halothane -
nitrous oxide combination was used. This combination re-
sulted in a dramatic increase in dopamine turnover in the 
mesencephalon, hypothalmus and cortex. Large increases in 
thalamic and cortical norepinephrine were also found. 
Several conclusions were drawn from this data 
(1) It was determined that adrenergic turnover is 
effected by the anesthetics ketamine, halothane, and 
nitrous oxide at clinical doses. This suggests a role 
for these neurotransmitter systems in anesthesia. 
(2) Dopamine and norepinephrine metabolism were found 
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to be independently altered by these anesthetic agents, 
indicating a possible distinct role for each neurotrans-
mitter. (3) Effects of these anesthetics were found not 
to be uniform throughout the brain. This could account 
for many of the discrepancies in previous turnover studies 
using whole brain. (4) The reversal of the halothane 
effects two hours post anesthesia denotes a strong temporal 
relationship between the state of anesthesia and· the 
alteration of adrenergic turnover. (5) Anesthetic agents 
which are clinically different were shown to also differ 
in their effect on central adrenergic turnover. (6) The 
data from this study coupled to evidence obtained from 
animal and human studies supports the concept of increased 
neuronal activity during anesthesia in proposed inhibitory 
transmitter systems. 
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Awake Control 
Ketamine 
Halothane 
Nitrous Oxide 
Halothane + 
Nitrous Oxide 
Halothane 
Recovery 
* Mean ± SE 
APPENDIX A 
B R A I N W E I G H T S 
(in grams) 
MES. THAL. HYPO. CORT. 
0.75±.02* 0.55±.02 0.35±.01 1.98±.05 
0.74±.03 0.56±.02 0.33±.02 1.99±.03 
0.72±.02 0.58±.02 0.34±.01 1.95±.06 
0.75±.02 0.58±.02 0.36±.02 2.08±.05 
0.70±.03 0.54±.04 0.32±.03 2.05±.04 
0.71±.04 0.60±.03 0.33±.01 2.14±.06 
MES. = Mesencephalon 
THAL.= Thalamus 
HYPO.= Hypothalamus 
CORT.= Cortex 
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APPENDIX B 
M 0 N I T 0 R I N G V A L U E S 
Parameter Range of Values 
1) Pao 2 350 - 450 torr 
2) PaC0 2 34 - 39 torr 
3) pH 7.34- 7.40 
4) Temperature 39 - 39.5°C 
5) X Arterial Blood Pressure 92 - 110 torr 
6) Halothane Blood Levels 12.3 ± 0.8 mg% 
Note: All values shown are within normal limits for rabbit. 
The Pao 2 r~nge for ketamine was 86 - 100 torr due to room air spontaneous ventilation. 
Halothane blood levels are consistent with 
published values. 
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